SB 1174: Medi-Cal: children: prescribing patterns: psychotropic medications.
- Session Year: 2015-2016
- House: Senate
- Latest Version Date: 2016-09-29
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would, until January 1, 2027, require the State Department of Health Care Services and the State Department of Social Services, pursuant to a specified data-sharing agreement, to provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be drawn from existing data sources maintained by the departments and shared pursuant to a data-sharing agreement and would require that, every 5 years, the board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. The bill would require the board to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board. Commencing July 1, 2017, the bill would require the board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would, until January 1, 2027, require the board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the board, on or before January 1, 2022, to conduct an internal review of those activities and to revise procedures relating to those activities, if determined to be necessary. The bill would require the State Department of Health Care Services to disseminate treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would, until January 1, 2027, require the State Department of Health Care Services and the State Department of Social Services, pursuant to a specified data-sharing agreement, to provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be drawn from existing data sources maintained by the departments and shared pursuant to a data-sharing agreement and would require that, every 5 years, the board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. The bill would require the board to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board. Commencing July 1, 2017, the bill would require the board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would, until January 1, 2027, require the board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the board, on or before January 1, 2022, to conduct an internal review of those activities and to revise procedures relating to those activities, if determined to be necessary. The bill would require the State Department of Health Care Services to disseminate treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would would, until January 1, 2027, require the State Department of Health Care Services and the State Department of Social Services, pursuant to a specified data-sharing agreement, to provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be drawn from existing data sources maintained by the departments and shared pursuant to a data-sharing agreement and would require that, every 3 5 years, the board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. The bill would require the board to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board. Commencing July 1, 2017, the bill would require the board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would would, until January 1, 2027, require the board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the board, on or before January 1, 2022, to conduct an internal review of those activities and to revise procedures relating to those activities, if determined to be necessary. The bill would require the State Department of Health Care Services to disseminate treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the board to conduct on an annual basis an analysis of data State Department of Health Care Services and the State Department of Social Services, pursuant to a specified data-sharing agreement, to provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be drawn from existing data sources maintained by the departments and shared pursuant to a data-sharing agreement and would require that, every 3 years, the board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. The bill would require the board to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board. Commencing July 1, 2017, the bill would require the board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would require the board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the State Department of Health Care Services to disseminate treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the board to conduct on a quarterly an annual basis an analysis of data regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be drawn from existing data sources maintained by the departments and shared pursuant to a data-sharing agreement and would require that, every 3 years, the board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. The bill would require the board to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board. Commencing July 1, 2017, the bill would require the board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would require the board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the State Department of Health Care Services to disseminate treatment guidelines on an annual basis via email to any prescriber who meets one or more of specified prescribing patterns, such as prescribing any class of psychotropic medication for a child who is 5 years of age or younger, or prescribing a dosage that exceeds the amount recommended for children. through its existing communications with Medi-Cal providers, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the Medical Board of California board to conduct on a quarterly basis an analysis of data regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for specified children and minors placed in foster care using data provided by the State Department of Health Care Services and the State Department of Social Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be shared pursuant to a data-sharing agreement and would require that, every 3 years, the Medical Board of California, board, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. Commencing July 1, 2017, the bill would require the Medical Board of California board to report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would require the Medical Board of California board to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the Medical Board of California to disseminate guidelines for the prescribing of psychotropic medications to children and adolescents on an annual basis to any prescriber who has been flagged for review. State Department of Health Care Services to disseminate guidelines on an annual basis via email to any prescriber who meets one or more of specified prescribing patterns, such as prescribing any class of psychotropic medication for a child who is 5 years of age or younger, or prescribing a dosage that exceeds the amount recommended for children. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the Medical Board of California to conduct on a quarterly basis an analysis of data regarding Medi-Cal prescribers physicians and their prescribing patterns of psychotropic medications and related services using data provided by the State Department of Health Care Services and the State Department of Social Services. The bill would require the data to include a breakdown by specified population categories of children, including children in foster care. Services, as prescribed. The bill would require that the data concerning psychotropic medications and related services be shared pursuant to a data-sharing agreement and would require that, every 3 years, the Medical Board of California, the State Department of Health Care Services, and the State Department of Social Services consult and revise the methodology, if determined to be necessary. Commencing July 1, 2017, the bill would require the Medical Board of California to report quarterly annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would require the Medical Board of California to review the data in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the Medical Board of California to disseminate guidelines for the prescribing of psychotropic medications to children and adolescents on an annual basis to any prescriber who has been flagged for review. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law, the Medical Practice Act, among other things provides for the licensure and regulation of physicians and surgeons by the Medical Board of California. Under existing law, the boards responsibilities include enforcement of the disciplinary and criminal provisions of the act.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the State Department of Health Care Services and the State Department of Social Services to, on an ongoing basis, conduct Medical Board of California to conduct on a quarterly basis an analysis of data regarding Medi-Cal prescribers and their prescribing patterns for all children enrolled in and receiving services pursuant to the Medi-Cal program. of psychotropic medications and related services using data provided by the State Department of Health Care Services and the State Department of Social Services. The bill would require the analysis to include the data to include a breakdown of data by specified population categories, categories of children, including children in foster care. Commencing July 1, 2017, the bill would require the State Department of Health Care Services and the State Department of Social Services to report quarterly to the Medical Board of California and to the Legislature of the ongoing analysis. Medical Board of California to report quarterly to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of the data. The bill would require the Medical Board of California to review the analysis data in order to determine if any potential violations of law or departures from excessive prescribing of psychotropic medications inconsistent with the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified. The bill would require the board to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services, including early and periodic screening, diagnosis, and treatment for any individual under 21 years of age. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law establishes a statewide system of child welfare services, administered by the State Department of Social Services, with the intent that all children are entitled to be safe and free from abuse and neglect.
This bill would require the State Department of Health Care Services and the State Department of Social Services to, on an ongoing basis, conduct an analysis of data regarding Medi-Cal prescribers and their prescribing patterns for all children enrolled in and receiving services pursuant to the Medi-Cal program. The bill would require the analysis to include a breakdown of data by specified population categories, including children in foster care. Commencing July 1, 2017, the bill would require the State Department of Health Care Services and the State Department of Social Services to report quarterly to the Medical Board of California and to the Legislature of the ongoing analysis. The bill would require the Medical Board of California to review the analysis in order to determine if any potential violations of law or departures from the standard of care exist and conduct an investigation, if warranted, and would require the board to take disciplinary action, as specified.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The State Department of Health Care Services shall disseminate the treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, such as the departments Internet Web site or provider bulletins.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(f)On or before January 1, 2022, and in conjunction with the consultation with the State Department of Social Services and the State Department of Health Care Services required by subdivision (a) of Section 14028 of the Welfare and Institutions Code, the Medical Board of California shall conduct an internal review of its data review, investigative, and disciplinary activities undertaken pursuant to this section for the purpose of determining the efficacy of those activities and shall revise its procedures relating to those activities, if determined to be necessary.
(g)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)(1)In order to ensure appropriate oversight of psychotropic medications prescribed for children, pursuant to Section 2245 of the Business and Professions Code, the department and the State Department of Social Services, pursuant to a data-sharing agreement that shall meet the requirements of all applicable state and federal laws and regulations, shall provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (c). The data concerning psychotropic medications and related services shall be drawn from existing data sources maintained by the departments. Every five years, the Medical Board of California, the department, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(2)At minimum, the department, on an annual basis, shall share with the Medical Board of California data, including, but not limited to, pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 90 days or more. Prior to the release of this data, personal identifiers such as name, date of birth, address, and social security number shall be removed and a unique identifier shall be submitted. For each foster child who falls into these categories, the department shall submit the following information to the board:
(A)A list of the psychotropic medications prescribed.
(B)The start and stop dates, if any, for each psychotropic medication prescribed.
(C)The prescribers name and contact information.
(D)The childs or adolescents year of birth.
(E)Any other information that is deidentified and necessary to the Medical Board of California to allow the board to exercise its statutory authority as an oversight entity.
(F)The unit and quantity of the medication and the number of days supply of the medication.
(b)The Medical Board of California shall contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board pursuant to subdivision (a). The consultant shall consider the treatment guidelines published by the department and the State Department of Social Services when assessing prescribing patterns.
(c)The Medical Board of California, pursuant to subdivision (a), shall analyze prescribing patterns by population for both of the following:
(1)Children adjudged as dependent children under Section 300 and placed in foster care.
(2)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(d)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The State Department of Health Care Services shall disseminate the treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, such as the departments Internet Web site or provider bulletins.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(f)On or before January 1, 2022, and in conjunction with the consultation with the State Department of Social Services and the State Department of Health Care Services required by subdivision (a) of Section 14028 of the Welfare and Institutions Code, the Medical Board of California shall conduct an internal review of its data review, investigative, and disciplinary activities undertaken pursuant to this section for the purpose of determining the efficacy of those activities and shall revise its procedures relating to those activities, if determined to be necessary.
(g)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)(1)In order to ensure appropriate oversight of psychotropic medications prescribed for children, pursuant to Section 2245 of the Business and Professions Code, the department and the State Department of Social Services, pursuant to a data-sharing agreement that shall meet the requirements of all applicable state and federal laws and regulations, shall provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (c). The data concerning psychotropic medications and related services shall be drawn from existing data sources maintained by the departments. Every five years, the Medical Board of California, the department, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(2)At minimum, the department, on an annual basis, shall share with the Medical Board of California data, including, but not limited to, pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 90 days or more. Prior to the release of this data, personal identifiers such as name, date of birth, address, and social security number shall be removed and a unique identifier shall be submitted. For each foster child who falls into these categories, the department shall submit the following information to the board:
(A)A list of the psychotropic medications prescribed.
(B)The start and stop dates, if any, for each psychotropic medication prescribed.
(C)The prescribers name and contact information.
(D)The childs or adolescents year of birth.
(E)Any other information that is deidentified and necessary to the Medical Board of California to allow the board to exercise its statutory authority as an oversight entity.
(F)The unit and quantity of the medication and the number of days supply of the medication.
(b)The Medical Board of California shall contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board pursuant to subdivision (a). The consultant shall consider the treatment guidelines published by the department and the State Department of Social Services when assessing prescribing patterns.
(c)The Medical Board of California, pursuant to subdivision (a), shall analyze prescribing patterns by population for both of the following:
(1)Children adjudged as dependent children under Section 300 and placed in foster care.
(2)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(d)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The State Department of Health Care Services shall disseminate the treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, such as the departments Internet Web site or provider bulletins.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(f)On or before January 1, 2022, and in conjunction with the consultation with the State Department of Social Services and the State Department of Health Care Services required by subdivision (a) of Section 14028 of the Welfare and Institutions Code, the Medical Board of California shall conduct an internal review of its data review, investigative, and disciplinary activities undertaken pursuant to this section for the purpose of determining the efficacy of those activities and shall revise its procedures relating to those activities, if determined to be necessary.
(g)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)(1)In order to ensure appropriate oversight of psychotropic medications prescribed for children, pursuant to Section 2245 of the Business and Professions Code, the department and the State Department of Social Services, pursuant to a data-sharing agreement that shall meet the requirements of all applicable state and federal laws and regulations, shall provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (c). The data concerning psychotropic medications and related services shall be drawn from existing data sources maintained by the departments. Every three five years, the Medical Board of California, the department, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(2)At minimum, the department, on an annual basis, shall share with the Medical Board of California data, including, but not limited to, pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 90 days or more. Prior to the release of this data, personal identifiers such as name, date of birth, address, and social security number shall be removed and a unique identifier shall be submitted. For each foster child who falls into these categories, the department shall submit the following information to the board:
(A)A list of the psychotropic medications prescribed.
(B)The start and stop dates, if any, for each psychotropic medication prescribed.
(C)The prescribers name and contact information.
(D)The childs or adolescents year of birth.
(E)Any other information that is deidentified and necessary to the Medical Board of California to allow the board to exercise its statutory authority as an oversight entity.
(F)The unit and quantity of the medication and the number of days supply of the medication.
(b)The Medical Board of California shall contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board pursuant to subdivision (a). The consultant shall consider the treatment guidelines published by the department and the State Department of Social Services when assessing prescribing patterns.
(c)The Medical Board of California, pursuant to subdivision (a), shall analyze prescribing patterns by population for both of the following:
(1)Children adjudged as dependent children under Section 300 and placed in foster care.
(2)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(d)This section shall remain in effect only until January 1, 2027, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2027, deletes or extends that date.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The State Department of Health Care Services shall disseminate the treatment guidelines on an annual basis through its existing communications with Medi-Cal providers, such as the departments Internet Web site or provider bulletins.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)(1)The Medical Board of California shall conduct on an annual basis or as requested an analysis of In order to ensure appropriate oversight of psychotropic medications prescribed for children, pursuant to Section 2245 of the Business and Professions Code, the department and the State Department of Social Services, pursuant to a data-sharing agreement that shall meet the requirements of all applicable state and federal laws and regulations, shall provide the Medical Board of California with information regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (c) using data provided by the department in collaboration with the State Department of Social Services. (c). The data concerning psychotropic medications and related services shall be drawn from existing data sources maintained by the department and the State Department of Social Services and shared pursuant to a data-sharing agreement that meets the requirements of all applicable state and federal laws and regulations. departments. Every three years, the Medical Board of California, the department, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(2)At minimum, the department, on an annual basis, shall share with the Medical Board of California data, including, but not limited to, pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 60 90 days or more, who are five years of age or younger and prescribed one or more psychotropic medications, and who are or have been on two or more antipsychotic medications for 60 days or more. Prior to the release of this data, personal identifiers such as name, date of birth, address, and social security number shall be removed and a unique identifier shall be submitted. For each foster child who falls into these categories, the department shall submit the following information to the board:(A)A list of the psychotropic medications prescribed.(B)The start and stop dates, if any, for each psychotropic medication prescribed.(C)The prescribers name and contact information.(D)The childs or adolescents year of birth.(E)The diagnoses received on nonpharmacy claims, including all associated dates of claim and service and the associated CPT code for the claim or service.
(E)Any other information that is deidentified and necessary to the Medical Board of California to allow the board to exercise its statutory authority as an oversight entity.
(F)The unit and quantity of the medication and the number of days supply of the medication.(G)The childs or adolescents weight.
(b)The Medical Board of California shall contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board pursuant to subdivision (a). The consultant shall consider the treatment guidelines published by the department and the State Department of Social Services when assessing prescribing patterns.
(c)The Medical Board of California, pursuant to subdivision (a), shall analyze prescribing patterns by population for both of the following:
(1)Children adjudged as dependent children under Section 300 and placed in foster care.
(2)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The State Department of Health Care Services shall disseminate the treatment guidelines on an annual basis via email to any prescriber who meets the data requirement threshold for prescribing psychotropic medications to children and adolescents established in subdivision (c) of Section 14028 of the Welfare and Institutions Code. through its existing communications with Medi-Cal providers, such as the departments Internet Web site or provider bulletins.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)(1)The Medical Board of California shall conduct on a quarterly basis an annual basis or as requested an analysis of Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (b) (c) using data provided quarterly by the department in collaboration with the State Department of Social Services that shall include, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. Services. The data concerning psychotropic medications and related services shall be drawn from existing data sources maintained by the department and the State Department of Social Services and shared pursuant to a data-sharing agreement that meets the requirements of all applicable state and federal laws and regulations. Every three years, the Medical Board of California, the State Department of Health Care Services, department, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(2)At minimum, the department, on an annual basis, shall share with the Medical Board of California data, including, but not limited to, pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 60 days or more, who are five years of age or younger and prescribed one or more psychotropic medications, and who are or have been on two or more antipsychotic medications for 60 days or more. Prior to the release of this data, personal identifiers such as name, date of birth, address, and social security number shall be removed and a unique identifier shall be submitted. For each foster child who falls into these categories, the department shall submit the following information to the board:
(A)A list of the psychotropic medications prescribed.
(B)The start and stop dates, if any, for each psychotropic medication prescribed.
(C)The prescribers name and contact information.
(D)The childs or adolescents year of birth.
(E)The diagnoses received on nonpharmacy claims, including all associated dates of claim and service and the associated CPT code for the claim or service.
(F)The unit and quantity of the medication and the number of days supply of the medication.
(G)The childs or adolescents weight.
(b)The Medical Board of California shall contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided to the board pursuant to subdivision (a). The consultant shall consider the treatment guidelines published by the department and the State Department of Social Services when assessing prescribing patterns.
(b) (1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include a breakdown
(c)The Medical Board of California, pursuant to subdivision (a), shall analyze prescribing patterns by population of all for both of the following:
(A)Children prescribed psychotropic medications in managed care and fee-for-service settings.
(B)
(1)Children adjudged as dependent children under Section 300 and placed in foster care.
(C)
(2)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(2)The data provided to the medical board as described in paragraph (1) shall include total rate and age stratifications that include the following:
(A)Birth to five years of age, inclusive.
(B)Six to 11 years of age, inclusive.
(C)Twelve to 17 years of age, inclusive.
(c)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include the information listed in paragraph (2) for each prescriber with a pattern of prescribing that includes one or more of the following:
(A)Prescriptions for any class of psychotropic medication for a child who is five years of age or younger.
(B)Prescriptions for concurrent administration of two or more antipsychotic medications that exceed 60 days.
(C)Prescriptions for concurrent administration of three or more psychotropic medications exceeding 60 days.
(D)Prescriptions for a dosage that exceeds the amount recommended for children.
(2)The following information shall be included for each prescriber described in paragraph (1):
(A)Prescriber name, specialty, location, and contact information.
(B)The childs gender and year of birth.
(C)A list of the psychotropic medications prescribed, diagnosis, and the medication start and end date.
(D)Unit of each medication, quantity of each medication, the days supply, and the prescription fill date.
(E)The childs weight.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The Medical Board of California shall disseminate guidelines for the prescribing of psychotropic medications to children and adolescents on an annual basis to any prescriber who has been flagged for review. State Department of Health Care Services shall disseminate guidelines on an annual basis via email to any prescriber who meets the data requirement threshold for prescribing psychotropic medications to children and adolescents established in subdivision (c) of Section 14028 of the Welfare and Institutions Code.
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)The Medical Board of California shall conduct on a quarterly basis an analysis of Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services for individuals described in subparagraphs (B) and (C) of paragraph (1) of subdivision (b) using data provided quarterly by the department in collaboration with the State Department of Social Services that shall include, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. The data concerning psychotropic medications and related services shall be shared pursuant to a data-sharing agreement that meets the requirements of all applicable state and federal laws and regulations. Every three years, the Medical Board of California, the State Department of Health Care Services, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(b)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include a breakdown by population of all of the following:
(A)Children prescribed psychotropic medications in managed care and fee-for-service settings.
(B)Children adjudged as dependent children under Section 300 and placed in foster care.
(C)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(D)Children with developmental disabilities, as described in Section 4512.
(2)The data provided to the medical board as described in paragraph (1) shall include total rate and age stratifications that include the following:
(A)Birth to five years of age, inclusive.
(B)Six to 11 years of age, inclusive.
(C)Twelve to 17 years of age, inclusive.
(c)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include the information listed in paragraph (2) for each prescriber with a pattern of prescribing that includes one or more of the following:
(A)Prescriptions for any class of psychotropic medication for a child who is five years of age or younger.
(B)Prescriptions for concurrent administration of two or more antipsychotic medications that exceed 60 days.
(C)Prescriptions for concurrent administration of three or more psychotropic medications exceeding 60 days.
(D)Prescriptions for a dosage that exceeds the amount recommended for children.
(2)The following information shall be included for each prescriber described in paragraph (1):
(A)Prescriber name, specialty, location, and contact information.
(B)The childs gender and year of birth.
(C)A list of the psychotropic medications prescribed, diagnosis, and the medication start and end date.
(D)Unit of each medication, quantity of each medication, the days supply, and the prescription fill date.
(E)The childs weight.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)The Medical Board of California shall disseminate guidelines for the prescribing of psychotropic medications to children and adolescents on an annual basis to any prescriber who has been flagged for review.
(b)
(c)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(c)
(d)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(d)
(e)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report quarterly annually to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)The Medical Board of California shall conduct on a quarterly basis an analysis of Medi-Cal and managed care prescribers physicians and their prescribing patterns of psychotropic medications and related services using data provided quarterly by the department in collaboration with the State Department of Social Services that shall include, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. The data concerning psychotropic medications and related services shall be shared pursuant to a data-sharing agreement that meets the requirements of all applicable state and federal laws and regulations. Every three years, the Medical Board of California, the State Department of Health Care Services, and the State Department of Social Services shall consult and revise the methodology, if determined to be necessary.
(b)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include a breakdown by population of all of the following:
(A)Children prescribed psychotropic medications in managed care and fee-for-service settings.
(B)Children adjudged as dependent children under Section 300 and placed in foster care.
(C)Children in juvenile halls, as described in Section 850, and children placed in ranches, camps, or other facilities, as described in Section 880.
(D)
(C)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(E)
(D)Children with developmental disabilities, as described in Section 4512.
(2)The data provided to the medical board as described in paragraph (1) shall include total rate and age stratifications that include the following:
(A)Birth to five years of age, inclusive.
(B)Six to 11 years of age, inclusive.
(C)Twelve to 17 years of age, inclusive.
(c)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include the information listed in paragraph (2) for each prescriber with a pattern of prescribing that includes one or more of the following:
(A)Prescriptions for any class of psychotropic medication for a child who is five years of age or younger.
(B)Prescriptions for concurrent administration of two or more antipsychotic medications that exceed 60 days.
(C)Prescriptions for concurrent administration of three or more psychotropic medications exceeding 60 days.
(D)Prescriptions for a dosage that exceeds the amount recommended for children.
(2)The following information shall be included for each prescriber described in paragraph (1):
(A)Prescriber name, specialty, location, and contact information.
(B)The childs gender and year of birth.
(C)A list of the psychotropic medications prescribed, diagnosis, and the medication start and end date.
(D)Unit of each medication, quantity of each medication, the days supply, and the prescription fill date.
(E)The childs weight.
(a)In order to ensure that its resources are maximized for the protection of the public, the Medical Board of California shall prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Cases involving any of the following allegations shall be handled on a priority basis, as follows, with the highest priority being given to cases in the first paragraph:
(1)Gross negligence, incompetence, or repeated negligent acts that involve death or serious bodily injury to one or more patients, such that the physician and surgeon represents a danger to the public.
(2)Drug or alcohol abuse by a physician and surgeon involving death or serious bodily injury to a patient.
(3)Repeated acts of clearly excessive prescribing, furnishing, or administering of controlled substances, or repeated acts of prescribing, dispensing, or furnishing of controlled substances without a good faith prior examination of the patient and medical reason therefor. However, in no event shall a physician and surgeon prescribing, furnishing, or administering controlled substances for intractable pain consistent with lawful prescribing, including, but not limited to, Sections 725, 2241.5, and 2241.6 of this code and Sections 11159.2 and 124961 of the Health and Safety Code, be prosecuted for excessive prescribing and prompt review of the applicability of these provisions shall be made in any complaint that may implicate these provisions.
(4)Repeated acts of clearly excessive recommending of cannabis to patients for medical purposes, or repeated acts of recommending cannabis to patients for medical purposes without a good faith prior examination of the patient and a medical reason for the recommendation.
(5)Sexual misconduct with one or more patients during a course of treatment or an examination.
(6)Practicing medicine while under the influence of drugs or alcohol.
(7)Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor.
(b)The board may by regulation prioritize cases involving an allegation of conduct that is not described in subdivision (a). Those cases prioritized by regulation shall not be assigned a priority equal to or higher than the priorities established in subdivision (a).
(c)The Medical Board of California shall indicate in its annual report mandated by Section 2312 the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category specified in subdivisions (a) and (b).
SEC. 2.Section 2245 is added to the Business and Professions Code, to read:2245.(a)The Medical Board of California on a quarterly basis shall review the data provided pursuant to Section 14028 of the Welfare and Institutions Code by the State Department of Health Care Services and the State Department of Social Services in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, shall conduct an investigation.
(b)If, after an investigation, the Medical Board of California concludes that there was a violation of law, the board shall take disciplinary action, as appropriate, as authorized by Section 2227.
(c)If, after an investigation, the Medical Board of California concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, the board shall take action, as appropriate, as authorized by Section 2227.
(d)(1)Notwithstanding Section 10231.5 of the Government Code, commencing July 1, 2017, the Medical Board of California shall report quarterly to the Legislature, the State Department of Health Care Services, and the State Department of Social Services the results of the analysis of data described in Section 14028 of the Welfare and Institutions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 3.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)The Medical Board of California shall conduct on a quarterly basis an analysis of Medi-Cal and managed care prescribers and their prescribing patterns of psychotropic medications and related services using data provided quarterly by the department in collaboration with the State Department of Social Services that shall include, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications.
(b)(1)The data provided to the Medical Board of California pursuant to subdivision (a) shall include a breakdown by population of all of the following:
(A)Children prescribed psychotropic medications in managed care and fee-for-service settings.
(B)Children adjudged as dependent children under Section 300 and placed in foster care.
(C)Children in juvenile halls, as described in Section 850, and children placed in ranches, camps, or other facilities, as described in Section 880.
(D)A minor adjudged a ward of the court under Section 601 or 602 who has been removed from the physical custody of the parent and placed into foster care.
(E)Children with developmental disabilities, as described in Section 4512.
(2)The data provided to the medical board as described in paragraph (1) shall include total rate and age stratifications that include the following:
(A)Birth to five years of age, inclusive.
(B)Six to 11 years of age, inclusive.
(C)Twelve to 17 years of age, inclusive.
SECTION 1.Section 14028 is added to the Welfare and Institutions Code, to read:14028.(a)The department and the State Department of Social Services shall, on an ongoing basis, conduct an analysis of data regarding Medi-Cal prescribers and their prescribing patterns for all children enrolled in and receiving services pursuant to, the Medi-Cal program. The analysis shall include a breakdown of data by population of:
(1)Children in foster care.
(2)Children in juvenile hall, as described in Section 850.
(3)Children placed in out-of-home care.
(4)Children with developmental disabilities.
(b)(1)Notwithstanding Section 10235.1 of the Government Code, commencing July 1, 2017, the department and the State Department of Social Services shall report quarterly to the Medical Board of California and to the Legislature the results of the ongoing analysis of data described in subdivision (a). The Medical Board of California shall review the analysis in order to determine if any potential violations of law or departures from the standard of care exist and, if warranted, shall conduct an investigation. If after the investigation, the Medical Board of California concludes that there was a violation of law or departure from the standard of care, the board shall take disciplinary action, as appropriate, as authorized by Section 2220.5 of the Business and Professions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(a)The department and the State Department of Social Services shall, on an ongoing basis, conduct an analysis of data regarding Medi-Cal prescribers and their prescribing patterns for all children enrolled in and receiving services pursuant to, the Medi-Cal program. The analysis shall include a breakdown of data by population of:
(1)Children in foster care.
(2)Children in juvenile hall, as described in Section 850.
(3)Children placed in out-of-home care.
(4)Children with developmental disabilities.
(b)(1)Notwithstanding Section 10235.1 of the Government Code, commencing July 1, 2017, the department and the State Department of Social Services shall report quarterly to the Medical Board of California and to the Legislature the results of the ongoing analysis of data described in subdivision (a). The Medical Board of California shall review the analysis in order to determine if any potential violations of law or departures from the standard of care exist and, if warranted, shall conduct an investigation. If after the investigation, the Medical Board of California concludes that there was a violation of law or departure from the standard of care, the board shall take disciplinary action, as appropriate, as authorized by Section 2220.5 of the Business and Professions Code.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
|
Date
|
Status
|
|---|---|
| Aug 31, 2016 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 25, 2016 | Assembly amendments concurred in. (Ayes 38. Noes 0. Page 5405.) Ordered to engrossing and enrolling. |
| Aug 25, 2016 | Assembly amendments concurred in. (Ayes 37. Noes 0.) Ordered to engrossing and enrolling. |
| Aug 23, 2016 | Read third time. Passed. (Ayes 80. Noes 0. Page 6076.) Ordered to the Senate. |
| Aug 23, 2016 | Read third time. Passed. Ordered to the Senate. |
| Aug 23, 2016 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 19, 2016 | Read third time and amended. (Ayes 73. Noes 0. Page 5955.) |
| Aug 19, 2016 | Assembly Rule 69 suspended. (Ayes 48. Noes 23. Page 5945.) |
| Aug 19, 2016 | Ordered to third reading. |
| Aug 19, 2016 | Read third time and amended. |
| Aug 19, 2016 | Assembly Rule 69 suspended. |
| Aug 11, 2016 | Read second time. Ordered to third reading. |
| Aug 10, 2016 | From committee: Do pass. (Ayes 19. Noes 0.) (August 10). |
| Aug 3, 2016 | August 3 hearing postponed by committee. |
| Aug 3, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on APPR. |
| Aug 1, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on APPR. |
| Jun 28, 2016 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (June 28). Re-referred to Com. on APPR. |
| Jun 22, 2016 | Read second time and amended. Re-referred to Com. on B. & P. |
| Jun 21, 2016 | From committee: Do pass as amended and re-refer to Com. on B. & P. (Ayes 13. Noes 0.) (June 21). |
| Jun 15, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Jun 13, 2016 | Referred to Coms. on HEALTH and B. & P. |
| Jun 1, 2016 | In Assembly. Read first time. Held at Desk. |
| May 31, 2016 | Read third time. Passed. (Ayes 36. Noes 3. Page 4046.) Ordered to the Assembly. |
| May 31, 2016 | Read third time. Passed. (Ayes 36. Noes 3.) Ordered to the Assembly. |
| May 27, 2016 | From committee: Do pass. (Ayes 6. Noes 0. Page 4005.) (May 27). |
| May 27, 2016 | Read second time. Ordered to third reading. |
| May 27, 2016 | From committee: Do pass. (Ayes 6. Noes 0.) (May 27). |
| May 20, 2016 | Set for hearing May 27. |
| Apr 25, 2016 | April 25 hearing: Placed on APPR. suspense file. |
| Apr 15, 2016 | Set for hearing April 25. |
| Apr 12, 2016 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0. Page 3491.) (April 11). Re-referred to Com. on APPR. |
| Apr 12, 2016 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (April 11). Re-referred to Com. on APPR. |
| Apr 1, 2016 | Set for hearing April 11. |
| Mar 31, 2016 | Re-referred to Com. on B., P. & E.D. |
| Mar 29, 2016 | Re-referred to Com. on RLS. |
| Mar 29, 2016 | Withdrawn from committee. |
| Mar 28, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Mar 23, 2016 | April 13 hearing postponed by committee. |
| Mar 16, 2016 | Set for hearing April 13. |
| Mar 15, 2016 | April 6 set for first hearing canceled at the request of author. |
| Mar 15, 2016 | Set for hearing April 6. |
| Mar 3, 2016 | Referred to Coms. on HEALTH and HUMAN S. |
| Feb 19, 2016 | From printer. May be acted upon on or after March 20. |
| Feb 18, 2016 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 25, 2016 | Unfinished Business SB1174 McGuire Concurrence | Senate Floor |
Passed |
|
| Aug 23, 2016 | SB 1174 McGuire Senate Third Reading By BURKE | Assembly Floor |
Passed |
|
| Aug 19, 2016 | SB 1174 McGuire Senate Third Reading Amendment Set #1 | Assembly Floor |
Passed |
|
| Aug 10, 2016 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jun 28, 2016 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
|
| Jun 21, 2016 | Do pass as amended and be re-referred to the Committee on [Business and Professions] | Assembly Standing Committee on Health |
Passed |
|
| May 31, 2016 | Senate 3rd Reading SB1174 McGuire | Senate Floor |
Passed |
|
| May 27, 2016 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 25, 2016 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 11, 2016 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB |
UNFINISHED BUSINESS
Bill No: SB 1174
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 4/11/16
AYES: Hill, Berryhill, Block, Galgiani, Hernandez, Jackson, Mendoza, Wieckowski
NO VOTE RECORDED: Bates
SENATE APPROPRIATIONS COMMITTEE: 6-0, 5/27/16
AYES: Lara, Bates, Beall, Hill, McGuire, Mendoza
NO VOTE RECORDED: Nielsen
SENATE FLOOR: 36-3, 5/31/16
AYES: Allen, Anderson, Bates, Beall, Berryhill, Block, Cannella, De León, Fuller, Gaines, Galgiani, Glazer, Hall, Hancock, Hernandez, Hertzberg, Hill, Hueso, Huff, Jackson, Lara, Leno, Leyva, Liu, McGuire, Mendoza, Mitchell, Monning, Moorlach, Nguyen, Nielsen, Pavley, Roth, Vidak, Wieckowski, Wolk
NOES: Morrell, Pan, Stone
NO VOTE RECORDED: Runner
ASSEMBLY FLOOR: 80-0, 8/23/16 - See last page for vote
SOURCE: National Center for Youth Law
DIGEST: This bill adds the following causes of action to the Medical Board of California’s (MBC) list of priority cases for investigation and prosecution: “repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason”. This bill requires the Department of Health Care Services (DHCS) to provide data to MBC on psychotropic medications prescribed to foster youth and requires the MBC to analyze prescribing patterns to foster youth.
Assembly Amendments add sunset provisions to the requirement for DHCS to provide MBC data and the requirement for MBC analysis of prescribing data; and extend the timeframe for reporting from quarterly to annual as well as included changes necessary for implementation of the bill by DHCS, Department of Social Services (DSS) and MBC.
Existing law:
- Provides for the licensure and regulation of physicians and surgeons by the MBC pursuant to the Medical Practice Act (Act). (Business and Professions Code (BPC) Sections 2000 et seq.)
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substances without a good faith prior examination of the patient and medical reason to be handled as a high priority. Specifies that physicians and surgeons shall not be prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law. (BPC § 2220.05)
- Provides that only a juvenile court judicial officer shall have authority to make orders regarding the administration of psychotropic medications for a minor who has been adjudged a dependent of the court and removed from the physical custody of his or her parent. (Welfare and Institutions Code (WIC) § 369.5)
- Establishes a program of public health nursing in the child welfare services program that provides health-related case management services from a foster care public health nurse to coordinate with child welfare service workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications. Requires public health nurses to receive training related to psychotropic medications, as specified. (WIC § 16501.3)
- Requires DSS, in consultation with DHCS and other specified stakeholders, to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including authorized medications, pharmacy data including the quantity and dose, other available information regarding psychosocial interventions and incidents of polypharmacy. (WIC § 16501.4)
This bill:
- Adds “repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor” to the list of cases for which MBC must prioritize its investigative and prosecutorial resources.
- Requires DHCS and DSS, until January 1, 2027, to provide data to MBC regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications, including pharmacy claims data for all foster children who are or have been on three or more psychotropic medications for 90 days or more that includes:
- A list of the psychotropic medications prescribed;
- The start and stop dates, if any, for each psychotropic medication prescribed;
- The prescriber’s name and contact information;
- The child’s or adolescent’s year of birth;
- Any other information that is deidentified and necessary for MBC to exercise its statutory authority as an oversight entity and;
- The unit and quantity of the medication and the number of days’ supply of the medication.
- Requires MBC, until January 1, 2027, to contract for consulting services from, if available, a psychiatrist who has expertise and specializes in pediatric care for the purpose of reviewing the data provided in 2) above. Requires MBC to analyze prescribing patterns by population children adjudged as dependent children and placed in foster care and a minor adjudged a ward of the court who has been removed from the physical custody of the parent and placed into foster care.
Background
Psychotropic Medication. According to background information from recent Senate hearings on this issue, concern over the use of psychotropic medications among children has been well-documented in research journals and the mainstream media for more than a decade. The category of psychotropic medication is fairly broad, intending to treat symptoms of conditions ranging from attention deficit hyperactivity disorder (ADHD) to childhood schizophrenia. Some of the drugs used to treat these conditions are U.S. Food and Drug Administration (FDA) approved, including stimulants like Ritalin for ADHD, however only about 31 percent of psychotropic medications have been approved by the FDA for use in children or adolescents. It is estimated that more than 75 percent of the prescriptions written for psychiatric illness in this population are "off label" in usage, meaning they have not been approved by the FDA for the prescribed use, though the practice is legal and common across all manner of pharmaceuticals.
Anti-psychotic medications, used to treat more severe mental health conditions, include powerful brand-name drugs such as Haldol, Risperdal, Abilify, Seroquel and Zyprexa. They have very limited approval by the FDA for pediatric use beyond rare and severe conduct problems that are resistant to other forms of treatment, such as Tourette's syndrome, behavioral symptoms associated with autistic disorder, childhood schizophrenia, and bipolar disorder. However, the off-label use of these anti-psychotics among children is high, particularly among foster children. According to a study published in 2011, children who took antipsychotic medications were likely to suffer ill health effects including "cardio metabolic and endocrine side-effects" as well as significant weight gain. The authors recommended that collaboration between child and adolescent psychiatrists, general practitioners and pediatricians is essential to "reduce the likelihood of premature cardiovascular morbidity and mortality."
Compounding the potential for unintended side effects is the use of combinations of psychotropic medications, which foster youth are particularly likely to be prescribed, despite limited evidence of clinical efficacy. Protecting the health and well-being of children who are taking one or more psychotropic medications requires extensive and ongoing health and metabolic screenings to identify potential adverse effects quickly, however in practice many children many fail to receive ongoing screenings and adverse effects may go undetected causing permanent injury or death.
Medical Board Efforts to Provide Guidance to Licensees on Prescribing. The MBC made available to all licensees on its Web site, as well as through an e-mail to its licensee listserv, the DHCS and DSS’s statewide Quality Improvement Project (QIP) Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care, which states that “the use of psychotropic medication for children and youth is considered a non-routine intervention, used under specified circumstances and as only one strategy within a larger, more comprehensive treatment plan to provide for that child's safety and well-being”. MBC’s responsibilities in overseeing their licensees’ prescribing habits of psychotropic medications to foster youth are also a component of an audit currently being conducted by the California State Auditor pertaining to the oversight and monitoring of children in foster care who have been prescribed psychotropic medications.
At the October 2015 MBC meeting, the Board discussed strategies to help identify physicians who may be inappropriately prescribing psychotropic medications to foster youth as well as identify additional information needed from DHCS and DSS. However, there were concerns raised about the expectations of physicians based on the quality of information in the QIP’s Psychotropic Data Match Report. The MBC has expressed concerns that the data presented in the report may not be sufficient to make a decision as to appropriate prescribing practices for physicians working with foster youth.
The Board has, in the meantime, developed a notification process whereby individuals in the healthcare delivery system for foster youths can directly contact MBC staff if they believe a physician is inappropriately prescribing medication to children in foster care. After a complaint or notification is made, MBC staff will directly contact DSS to obtain all de-identified patient information for the foster child and the prescriber. The Board can then determine whether or not it will need patient records. DSS and the MBC can then obtain these patient records through a court order so that the Board can proceed with an investigation into the prescribing physician.
Data Sharing Efforts. MBC currently has a data user agreement (DUA) with DHCS and DSS in order to allow the MBC to receive information that does not breach the confidentiality of a patient. The DUA is based on conversations dating back to 2014 regarding the data needed for the MBC to identify physicians who may be inappropriately prescribing psychotropic medications to foster children. Upon receipt of its first set of data under the DUA, MBC enlisted a pediatric psychiatrist to review the data. The physician determined that the information provided through the agreement was not substantive enough to allow MBC to identify instances of any inappropriate prescribing and noted that additional information to assist in this effort would include the diagnosis associated with medication prescribed, the dosage of medication prescribed, the schedule or timing of dosage of medication prescribed and the weight of child or adolescent.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
According to the Assembly Appropriations Committee, costs to DHCS, MBC, and DSS are expected to be minor and absorbable, as this bill largely aligns with existing activities that are not likely to cease in absence of this bill.
National Center for Youth Law (source)
Bay Area Youth Center
California Youth Connection
California Youth Empowerment Network
Children Now
Consumer Attorneys of California
Consumer Watchdog
Contra Costa County
Family Voices of California
First Focus Campaign for Children
John Burton Foundation
Kids in Common
Madera County Department of Social Services
Peers Envisioning and Engaging in Recovery Services
San Luis Obispo County Department of Social Services
Sunny Hills Services
Therapists for Peace and Justice
Woodland Community College Foster & Kinship Care Education
Youth Law Center
Two individuals
OPPOSITION: (Verified 8/23/16)
California Academy of Child and Adolescent Psychiatry
ARGUMENTS IN SUPPORT: Numerous groups support this bill, citing the frequency of psychotropic drug prescription among foster youth. These groups call for an appropriate oversight mechanism that can help identify outlying prescribers. They argue that this bill will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children.
ARGUMENTS IN OPPOSITION: The California Academy of Child and Adolescent Psychiatry believes that initiating investigations as proposed will ultimately target prescribing physicians who specialize with patients with severe mental health difficulties. The organization notes that it is unclear how MBC would make a basis for an accusation of professional conduct on the date proposed to be provided to the board and would like to see a review panel made up of qualified providers who could review outlying prescribing practices and discuss, educate and offer advice to prescribers who are outside the community standard.
ASSEMBLY FLOOR: 80-0, 8/23/16
AYES: Achadjian, Alejo, Travis Allen, Arambula, Atkins, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Quirk, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Rendon
8/23/16 20:02:58
**** END ****
SENATE THIRD READING
STR Bill Id:SB 1174
Author:(McGuire)
As Amended Ver:August 3, 2016
Majority vote
SENATE VOTE: 36-3
Committee | Votes | Ayes | Noes |
Health | 13-0 | Wood, Maienschein, Bonilla, Burke, Campos, Roger Hernández, Lackey, Nazarian, Ridley-Thomas, Santiago, Steinorth, Thurmond, Waldron | |
Business & Professions | 16-0 | Salas, Brough, Baker, Bloom, Campos, Chávez, Dahle, Dodd, Eggman, Gatto, Gomez, Holden, Jones, Mullin, Ting, Wood | |
Appropriations | 19-0 | Gonzalez, Bigelow, Bloom, Bonilla, Bonta, Calderon, Daly, Eggman, Gallagher, Eduardo Garcia, Holden, Jones, Obernolte, Quirk, Santiago, Wagner, Weber, Wood, Chu |
|
SUMMARY: Requires the State Department of Health Care Services (DHCS) and the State Department of Social Services (DSS), to provide the Medical Board of California (MBC) with information to conduct an analysis of Medi-Cal and managed care prescribing patterns of psychotropic medications to determine if excessive prescribing exists and, if so, to take appropriate action and adds repeated acts of clearly excessive prescribing psychotropic medications to a minor without a good faith prior examination to the list of cases that MBC must prioritize investigating and prosecuting.
EXISTING LAW:
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substance without a good faith prior examination of the patient and medical reason to be handled as a high priority. Prohibits physicians and surgeons from being prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law.
- Provides that only a juvenile court judicial officer has the authority to make orders regarding the administration of psychotropic medications for a minor who is a dependent of the court. Requires that court authorization for the administration of psychotropic medications be based on a request from a physician, indicating the reasons for the request, a description of the child's diagnosis and behavior, the expected results of the medication, and a description of any side effects of the medication. Requires the Judicial Council, on or before July 1, 2016, to adopt rules and develop appropriate forms for implementing this requirement. Requires the rules and forms to address all of the following:
- The child and his or her caregiver and Court Appointed Special Advocate (CASA), if any, have an opportunity to provide input on the medications being prescribed;
- Information regarding the child's overall mental health assessment and treatment plan is provided to the court;
- Information regarding the rationale for the proposed medication, provided in the context of past and current treatment efforts, is provided to the court; and,
- Guidance is provided to the court on how to evaluate the request for authorization.
- Requires that the court either approve or deny a physician's request, pursuant to 2) above, within seven business days of its receipt.
- Establishes a program of public health nursing in the child welfare services (CWS) program that provides health-related case management services from a foster care public health nurse to coordinate with CWS workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications.
- Requires DSS, in consultation with DHCS, and other specified stakeholders to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including paid claims and managed care encounters. Requires DSS to develop training, in consultation DHCS and various other agencies that may be provided to county child welfare social workers and others that addresses the use of psychotropic medications.
FISCAL EFFECT: According to the Assembly Appropriations Committee, costs to DHCS, MBC, and DSS are expected to be minor and absorbable, as this bill largely aligns with existing activities that are not likely to cease in absence of this bill.
COMMENTS: According to the author, this bill stems from a growing and significant concern over the excessive prescribing of psychotropic medication to foster youth in California. It follows a series of hearings held by the California Senate Committees on Health and Human Services regarding the oversight and monitoring of psychotropic medication and mental health services for youth in foster care. Even with the growing attention to this situation, the problem is now more severe than ever and California's 63,000 foster youth are the ones who are suffering the consequences of our state's inaction and lack of oversight over the past 15 years. According to the author, despite our current safeguards in place – the JV-220 process, whereby judges decide what medications and at what dosage are provided to foster youth, over the past fifteen years the rate of foster youth prescribed psychotropic medication has increased 14 fold. The author states that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic (an estimated 75% of them for an off label use) and 36% are prescribed multiple medications.
The author states that, as reported by the San Jose Mercury News, the federal Food and Drug Administration authorizes antipsychotics for children only in cases of severe mental illness, but evidence suggests medical professionals often prescribe them to California foster children for behavior problems. According to the author, California spends more on psychotropic drugs for foster children than on any other kind of medication. In the last decade, the state spent more than $226 million on psychotropic meds for foster children, 72% of total drug spending for this population. Additionally, there are substantial long-term costs of treating side effects associated with these medications. Furthermore, teens in foster care are three and a half times more likely to be prescribed psych medication than their peers who are not in foster care. While the federal Child and Family Services Improvement and Innovation Act of 2011 requires each state to oversee and monitor the use of psychotropic medications, California currently has no requirements to identify those who are over-prescribing medication to foster youth. California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices.
The California State Auditor (CSA) is currently engaged in an audit of foster youth and psychotropic medication. It is expected to be released in July or August of this year. According to the CSA Web site, the audit will provide independently developed and verified information related to DSS, DHCS, and a selection of county CWS agencies' oversight and monitoring of foster children who have been prescribed psychotropic medications, as well as a review of the availability and adequacy of other supportive services, such as mental health and substance abuse counseling. The audit will select and review four county CWS agencies – two counties identified as having a high prevalence of the use of psychotropic medications for foster children and two counties with a correspondingly low prevalence. The audit will also determine whether any other states have implemented innovations or oversight systems that have successfully reduced the use of psychotropic medications in foster children or improved their access to non-pharmacological supports, and evaluate whether California could benefit from some of these policies or practices.
The National Center for Youth Law (NCYL), the sponsor of this bill, argues that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects. While the vast majority of doctors prescribing medication are doing so appropriately, California still needs an oversight mechanism (among other reforms including funding robust trauma care services). Currently, California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices. NCYL noted that last year, DHCS and MBC adopted a one-year trial Data Use Agreement (DUA) that allows for the sharing of prescriber data in order to identify outlying prescribers. NCYL argues that such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing for our children. This will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children. Advokids, states in support of this bill that it operates the only free statewide telephone hotline providing legal information to anyone concerned about a foster child, and receives a high volume of calls from caregivers who are concerned about the lack of mental health services available to their foster children, many of whom have experienced multiple traumas in their lives. Advokids argues for high quality, accessible mental health services for foster children and the careful collection of data surrounding psychotropic medications to ensure the physical and emotional safety of foster youth and when warranted to investigate physicians who frequently prescribe over the recognized safety parameters for children.
MBC has a support if amended position on this bill. MBC requests additional information (included in the most recent version of this bill) and a sunset date so MBC can determine if the data provided is useful. MBC also has requested that the author amend this bill so that the education component is handled by DHCS since they are the Medi-Cal prescribers and the guidelines were created by DHCS and DSS. MBC notes that any information that can help MBC identify inappropriate prescribing can be utilized as a tool for MBC to use in its complaint and investigation process. However, once a possible inappropriate prescriber is identified, MBC will still have to go through its normal complaint and investigation process.
The California Academy of Child and Adolescent Psychiatry (CACAP) believes that initiating investigations as proposed will ultimately target prescribing physicians who specialize with patients with severe mental health difficulties. CACAP argues that it is unclear how MBC would make a basis for an accusation of unprofessional conduct on the data that is proposed to be provided. Additionally, this process would also discourage physicians from prescribing a psychotropic medication even when, in their professional judgement, it is in the best interest for the child. An investigation by MBC is a significant event. Even if the investigation should not result in disciplinary action, questions regarding whether or not a physician has ever been investigated by MBC come up often in interviews and credentialing reviews. While these red flag aren't as serious as a filed accusation, we believe the envisioned process will have a negative impact on the ability of the Medi-Cal system to recruit and retain high quality providers for Medi-Cal and Foster youth.
Analysis Prepared by: Paula Villescaz / HEALTH / (916) 319-2097 FN: 0003936
SENATE THIRD READING
STR Bill Id:SB 1174
Author:(McGuire)
As Amended Ver:August 19, 2016
Majority vote
SENATE VOTE: 36-3
Committee | Votes | Ayes | Noes |
Health | 13-0 | Wood, Maienschein, Bonilla, Burke, Campos, Roger Hernández, Lackey, Nazarian, Ridley-Thomas, Santiago, Steinorth, Thurmond, Waldron | |
Business & Professions | 16-0 | Salas, Brough, Baker, Bloom, Campos, Chávez, Dahle, Dodd, Eggman, Gatto, Gomez, Holden, Jones, Mullin, Ting, Wood | |
Appropriations | 19-0 | Gonzalez, Bigelow, Bloom, Bonilla, Bonta, Calderon, Daly, Eggman, Gallagher, Eduardo Garcia, Holden, Jones, Obernolte, Quirk, Santiago, Wagner, Weber, Wood, Chu |
SUMMARY: Requires the State Department of Health Care Services (DHCS) and the State Department of Social Services (DSS), to provide the Medical Board of California (MBC) with information to conduct an analysis of Medi-Cal and managed care prescribing patterns of psychotropic medications to determine if excessive prescribing exists and, if so, to take appropriate action and adds repeated acts of clearly excessive prescribing psychotropic medications to a minor without a good faith prior examination to the list of cases that MBC must prioritize investigating and prosecuting. Requires, on or before January 1, 2022, the MBC to conduct an internal review of its data review, investigative, and disciplinary activities and to revise its procedures relating to those activities if necessary and sunsets the provisions of this bill on January 1, 2027.
EXISTING LAW:
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substance without a good faith prior examination of the patient and medical reason to be handled as a high priority. Prohibits physicians and surgeons from being prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law.
- Provides that only a juvenile court judicial officer has the authority to make orders regarding the administration of psychotropic medications for a minor who is a dependent of the court. Requires that court authorization for the administration of psychotropic medications be based on a request from a physician, indicating the reasons for the request, a description of the child's diagnosis and behavior, the expected results of the medication, and a description of any side effects of the medication. Requires the Judicial Council, on or before July 1, 2016, to adopt rules and develop appropriate forms for implementing this requirement. Requires the rules and forms to address all of the following:
- The child and his or her caregiver and Court Appointed Special Advocate (CASA), if any, have an opportunity to provide input on the medications being prescribed;
- Information regarding the child's overall mental health assessment and treatment plan is provided to the court;
- Information regarding the rationale for the proposed medication, provided in the context of past and current treatment efforts, is provided to the court; and,
- Guidance is provided to the court on how to evaluate the request for authorization.
- Requires that the court either approve or deny a physician's request, pursuant to 2) above, within seven business days of its receipt.
- Establishes a program of public health nursing in the child welfare services (CWS) program that provides health-related case management services from a foster care public health nurse to coordinate with CWS workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications.
- Requires DSS, in consultation with DHCS, and other specified stakeholders to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including paid claims and managed care encounters. Requires DSS to develop training, in consultation DHCS and various other agencies that may be provided to county child welfare social workers and others that addresses the use of psychotropic medications.
FISCAL EFFECT: According to the Assembly Appropriations Committee, costs to DHCS, MBC, and DSS are expected to be minor and absorbable, as this bill largely aligns with existing activities that are not likely to cease in absence of this bill.
COMMENTS: According to the author, this bill stems from a growing and significant concern over the excessive prescribing of psychotropic medication to foster youth in California. It follows a series of hearings held by the California Senate Committees on Health and Human Services regarding the oversight and monitoring of psychotropic medication and mental health services for youth in foster care. Even with the growing attention to this situation, the problem is now more severe than ever and California's 63,000 foster youth are the ones who are suffering the consequences of our state's inaction and lack of oversight over the past 15 years. According to the author, despite our current safeguards in place – the JV-220 process, whereby judges decide what medications and at what dosage are provided to foster youth, over the past fifteen years the rate of foster youth prescribed psychotropic medication has increased 14 fold. The author states that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic (an estimated 75% of them for an off label use) and 36% are prescribed multiple medications.
The author states that, as reported by the San Jose Mercury News, the federal Food and Drug Administration authorizes antipsychotics for children only in cases of severe mental illness, but evidence suggests medical professionals often prescribe them to California foster children for behavior problems. According to the author, California spends more on psychotropic drugs for foster children than on any other kind of medication. In the last decade, the state spent more than $226 million on psychotropic meds for foster children, 72% of total drug spending for this population. Additionally, there are substantial long-term costs of treating side effects associated with these medications. Furthermore, teens in foster care are three and a half times more likely to be prescribed psych medication than their peers who are not in foster care. While the federal Child and Family Services Improvement and Innovation Act of 2011 requires each state to oversee and monitor the use of psychotropic medications, California currently has no requirements to identify those who are over-prescribing medication to foster youth. California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices.
The California State Auditor (CSA) is currently engaged in an audit of foster youth and psychotropic medication. It is expected to be released in July or August of this year. According to the CSA Web site, the audit will provide independently developed and verified information related to DSS, DHCS, and a selection of county CWS agencies' oversight and monitoring of foster children who have been prescribed psychotropic medications, as well as a review of the availability and adequacy of other supportive services, such as mental health and substance abuse counseling. The audit will select and review four county CWS agencies – two counties identified as having a high prevalence of the use of psychotropic medications for foster children and two counties with a correspondingly low prevalence. The audit will also determine whether any other states have implemented innovations or oversight systems that have successfully reduced the use of psychotropic medications in foster children or improved their access to non-pharmacological supports, and evaluate whether California could benefit from some of these policies or practices.
The National Center for Youth Law (NCYL), the sponsor of this bill, argues that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects. While the vast majority of doctors prescribing medication are doing so appropriately, California still needs an oversight mechanism (among other reforms including funding robust trauma care services). Currently, California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices. NCYL noted that last year, DHCS and MBC adopted a one-year trial Data Use Agreement (DUA) that allows for the sharing of prescriber data in order to identify outlying prescribers. NCYL argues that such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing for our children. This will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children. Advokids, states in support of this bill that it operates the only free statewide telephone hotline providing legal information to anyone concerned about a foster child, and receives a high volume of calls from caregivers who are concerned about the lack of mental health services available to their foster children, many of whom have experienced multiple traumas in their lives. Advokids argues for high quality, accessible mental health services for foster children and the careful collection of data surrounding psychotropic medications to ensure the physical and emotional safety of foster youth and when warranted to investigate physicians who frequently prescribe over the recognized safety parameters for children.
MBC has a support if amended position on this bill. MBC requests additional information (included in the most recent version of this bill) and a sunset date so MBC can determine if the data provided is useful. MBC also has requested that the author amend this bill so that the education component is handled by DHCS since they are the Medi-Cal prescribers and the guidelines were created by DHCS and DSS. MBC notes that any information that can help MBC identify inappropriate prescribing can be utilized as a tool for MBC to use in its complaint and investigation process. However, once a possible inappropriate prescriber is identified, MBC will still have to go through its normal complaint and investigation process.
The California Academy of Child and Adolescent Psychiatry (CACAP) believes that initiating investigations as proposed will ultimately target prescribing physicians who specialize with patients with severe mental health difficulties. CACAP argues that it is unclear how MBC would make a basis for an accusation of unprofessional conduct on the data that is proposed to be provided. Additionally, this process would also discourage physicians from prescribing a psychotropic medication even when, in their professional judgement, it is in the best interest for the child. An investigation by MBC is a significant event. Even if the investigation should not result in disciplinary action, questions regarding whether or not a physician has ever been investigated by MBC come up often in interviews and credentialing reviews. While these red flag aren't as serious as a filed accusation, we believe the envisioned process will have a negative impact on the ability of the Medi-Cal system to recruit and retain high quality providers for Medi-Cal and Foster youth.
Analysis Prepared by: Paula Villescaz / HEALTH / (916) 319-2097 FN: 0004665
Date of Hearing: August 10, 2016
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
SBPCA Bill Id:SB 1174
Author:(McGuire) – As Amended Ver:August 3, 2016
Policy Committee: | Health | Vote: | 13 - 0 |
Business and Professions | 16 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill addresses overuse of psychotropic drugs in the foster care system through data-sharing, analysis, and enforcement. Specifically, this bill:
- Adds repeated acts of clearly excessive prescribing psychotropic medications to a minor without a good faith prior examination to the list of cases that MBC must prioritize investigating and prosecuting.
- Requires the Medical Board of California (MBC) to analyze Medi-Cal prescribing patterns of psychotropic medications for foster youth to identify excessive prescribing and, if so identified, to take appropriate action. Specifically, it requires MBC to contract for consulting services from a child psychiatrist with specified credentials.
- Requires data to be shared with MBC by Department of Health Care Services (DHCS), in collaboration with the Department of Social Services (DSS), on an annual basis, and identifies the minimum data requirements.
FISCAL EFFECT:
Costs to DHCS, MBC, and DSS are expected to be minor and absorbable, as this bill largely aligns with existing activities that are not likely to cease in absence of this bill.
COMMENTS:
- Purpose. According to the author, this bill stems from a growing and significant concern over the excessive prescribing of psychotropic medication to foster youth in California. It follows a series of hearings held by the California Senate Committees on Health and Human Services regarding the oversight and monitoring of psychotropic medication and mental health services for youth in foster care. This bill is intended to complement and memorialize existing efforts to reduce inappropriate prescribing.
- Background. There has been significant effort at the state and federal levels in recent years to improve conditions for children in the foster care system. One concern is the high rate of prescribing of psychotropic drugs to foster youths. Legislative committee hearings were held in 2014 and 2015, which highlighted overreliance on psychotropic medication among foster youth, inappropriately high dosages of medication for children, inappropriate use of multiple medications, and usage occurring at longer durations than appropriate.
Some current efforts to address the problem include the following:
- A 2012 statewide Quality Improvement Project (QIP) convened DHCS and DSS to design, pilot, and evaluate effective practices to improve psychotropic medication use among children and youth in foster care. This project generated data and guidelines for appropriate use.
- DHCS and MBC have an existing Data Use Agreement whereby MBC can receive and analyze Medi-Cal prescribing data. This bill intends to codify that agreement.
- MBC has disseminated the guidelines created through the QIP that specify, among other things, that “the use of psychotropic medication for children and youth is considered a non-routine intervention, used under specified circumstances and as only one strategy within a larger, more comprehensive treatment plan to provide for that child's safety and well-being.”
- The California State Auditor is currently engaged in an audit of foster youth and psychotropic medication that is scheduled to be released later this year.
- Support. Advocates for children, foster children, and consumers support this bill. National Center for Youth Law, the bill's sponsor, contends that such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing for our children.
- Opposition. The California Academy of Child and Adolescent Psychiatry (Cal-ACAP) express opposition, citing concern that a broad group of physicians practicing within the standard of care could be subject to investigation.
- Prior Legislation. A number of bills have been enacted in recent years to enhance data-sharing, monitoring, oversight, and training related to excessive prescribing of psychotropic medication in the foster system, including SB 238 (Mitchell), Chapter 534, Statutes of 2015; SB 484 (Beall), Chapter 540, Statutes of 2015; and SB 319 (Beall), Chapter 535, Statutes of 2015.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Rudy Salas, Chair
SBPCA Bill Id:
Author:() – As Ver:
SENATE VOTE:
NOTE: This bill is double-referred, having been previously heard by the Assembly Committee on Health on June 21, 2016 and approved on a 13-0 vote.
SUBJECT:
SUMMARY: Requires the Medical Board of California (MBC) to conduct an analysis of data regarding Medi-Cal physicians and their prescribing patterns of psychotropic medications for foster youth using data provided by the Department of Health Care Services (DHCS) and the Department of Social Services (DSS), as specified. Requires that the data be shared pursuant to a data-sharing agreement and would require that, every 3 years, the MBC, DHCS, and the DSS consult and revise the methodology, if determined to be necessary. Requires the DHCS to disseminate guidelines on an annual basis via email to any prescriber, as specified. Requires the MBC to handle on a priority basis investigations of repeated acts of excessive prescribing, furnishing, or administering psychotropic medications to a minor, as specified.
EXISTING LAW:
- Establishes the MBC within the Department of Consumer Affairs (DCA) to license and regulate physician and surgeons and the Medical Practice Act (Act). (Business and Profession Code (BPC) § 2000 et seq.)
- Requires the MBC to take action against a physician and surgeon who is charged with unprofessional conduct, as specified. (BPC § 2234)
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substance without a good faith prior examination of the patient and medical reason to be handled as a high priority. Prohibits physicians and surgeons from being prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law. (BPC § 2220.05(a)(3))
- Requires the MBC to indicate in its annual report the number of temporary restraining orders, interim suspension orders, and disciplinary actions that are taken in each priority category, including those in 3) above. (BPC § 2220.05(c))
- Authorizes a physician and surgeon to prescribe for, or dispense or administer to, a person under his or her treatment for a medical condition dangerous drugs or prescription controlled substances for the treatment of pain or a condition causing pain, including, but not limited to, intractable pain. Provides that a physician and surgeon shall not be subject to disciplinary action for prescribing, dispensing, or administering dangerous drugs or prescription controlled substances according to certain requirements. Authorizes the MBC to take any action against a physician and surgeon who violates laws related to inappropriate prescribing. Provides that a physician and surgeon shall exercise reasonable care in determining whether a particular patient or condition, or the complexity of a patient’s treatment, including, but not limited to, a current or recent pattern of drug abuse, requires consultation with, or referral to, a more qualified specialist. (BPC § 2241.5)
- Provides that only a juvenile court judicial officer shall have authority to make orders regarding the administration of psychotropic medications for a minor is a dependent of the court and removed from the physical custody of his or her parent. Requires the Judicial Council to adopt rules of court and develop appropriate forms. (Welfare and Institutions Code (WIC) § 369.5)
- Establishes a program of public health nursing in the child welfare services (CWS) program that provides health-related case management services from a foster care public health nurse to coordinate with CWS workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications. (WIC § 16501.3)
- Requires DSS, in consultation with DHCS, and other specified stakeholders to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including paid claims and managed care encounters. Requires DSS to develop training, in consultation DHCS and various other agencies that may be provided to county child welfare social workers and others that addresses the use of psychotropic medications. (WIC § 16501.4)
THIS BILL:
- Adds repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination and medical reason therefor to the list of cases that MBC must prioritize for investigation and prosecution.
- Requires MBC to conduct on a quarterly basis an analysis of Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services using data provided quarterly by the DHCS in collaboration with the DSS.
- Requires that analysis to include, but not be limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications.
- Requires the data concerning psychotropic medications and related services to be shared pursuant to a data sharing agreement meeting the requirements of all applicable state and federal laws and regulations.
- Requires MBC, DHCS, and DSS to consult and revise the methodology every three years, if determined to be necessary.
- Requires the data provided to the MBC pursuant to 4) and 5) above include a breakdown by population of all of the following:
- Children prescribed psychotropic medications in managed care and fee-for-service settings;
- Children adjudged as dependent children, as specified, and placed in foster care; and,
- A minor adjudged a ward of the court who has been removed from the physical custody of the parent and placed into foster care.
- Specifies that the data provided to the MBC must include total rate and age stratifications that include the following:
- Birth to five years of age, inclusive;
- Six to 11 years of age, inclusive; and,
- Twelve to 17 years of age, inclusive.
- Requires the data provided to the MBC to include the information in 7) above for each prescriber with a pattern of prescribing that includes one or more of the following:
- Prescriptions for any class of psychotropic medication for a child who is five years of age or younger;
- Prescriptions for concurrent administration of two or more antipsychotic medications that exceed 60 days;
- Prescriptions for concurrent administration of three or more psychotropic medications exceeding 60 days; and,
- Prescriptions for a dosage that exceeds the amount recommended for children.
- Requires that the data provided to MBC pursuant to 2) above include the following information on each identified prescriber:
- Prescriber name, specialty, location, and contact information;
- The child’s gender and year of birth;
- List of the psychotropic medications prescribed, diagnosis, and the medication start and end date;
- Unit of the medication(s), quantity of the medication(s), the days supply, and prescription fill date: and,
- The child’s weight.
- Requires the MBC on a quarterly basis to review the data provided pursuant to 1) through 5) above in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, to conduct an investigation.
- Requires the DHCS to disseminate guidelines on an annual basis via email to any prescriber who meets the data requirement threshold for prescribing of psychotropic medications to children and adolescents, as specified.
- Requires the MBC to take disciplinary action if after an investigation, the MBC concludes that there was a violation of law, as specified.
- Requires the MBC to take action, as appropriate, if after an investigation the MBC concludes that there was excessive prescribing of psychotropic medications inconsistent with the standard of care, as specified.
- Requires, beginning July 1, 2017, the MBC to report annually to the DHCS, DSS, and the Legislature the results of the analysis of data.
FISCAL EFFECT: According to the Senate Appropriations Committee, this bill will result in:
- Ongoing costs up to $280,000 per year for the DHCS to analyze prescription drug claims data and compile required information for the Medical Board. The DHCS’s information technology systems contain prescription drug claims data (when combined with information from the DSS on foster care placements) to provide the data required to fulfill the requirements in the bill. The DHCS indicates that it will need two additional staff positions to compile the required data, stratify it into the required data categories, and report to the Medical Board.
However, as part of recent efforts to reduce overprescribing of psychotropic medications to foster youth, the DHCS has been working with the DSS and counties to identify foster youth being prescribed such medications. The Governor’s budget proposal includes an additional permanent position to continue this work. If approved by the Legislature, that new position may be able to also perform some or all of the requirements of this bill as well.
- Uncertain costs for the MBC to review the information provided by the DHCS and investigate instances where excessive prescribing may be occurring. According to the MBC, its staff is already reviewing data provided by the DHCS to look for cases of excessing prescribing. However, to the extent that such data analysis does uncover instances of excessing prescribing, this would lead to increased costs for investigations and potential disciplinary action by the MBC. While those instances of excessing prescribing may already be actionable by the MBC under current law and regulation, the data analysis required in the bill makes such investigations more likely to occur.
Unknown potential cost savings in the Medi-Cal program due to reduced inappropriate utilization of psychotropic medications by foster youth. To the extent that this bill contributes to ongoing efforts to reduce inappropriate use of those drugs by Medi-Cal beneficiaries, the bill is likely to reduce spending. Ongoing efforts in other states to reduce inappropriate prescribing have substantially reduced the use of these frequently expensive medications. The amount of any decrease in spending that could be attributed to this bill is uncertain, in part because there are several efforts underway by the state and the counties to reduce inappropriate prescribing of psychotropic drugs to foster youth.
COMMENTS:
Purpose. This bill is sponsored by the National Center for Youth Law. According to the author, “Over the past fifteen years, the rate of foster youth prescribed psychotropic medication has increased 1,400 percent. Nearly 1 in 4 California foster teens are prescribed psychotropic drugs; of those nearly 60 percent were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects. While the Child and Family Services Improvement and Innovation Act of 2011 requires each state to oversee and monitor the use of psychotropic medications with children in care, there are currently no requirements to identify those who are over prescribing medication to foster youth. The State of California has not been monitoring over prescribing because the data collection and data sharing system is not in place. Given the State has a responsibility to monitor the administration of these drugs and to ensure the health and well-being of foster children, we should implement a process that provides the appropriate oversight for these powerful medications. SB 1174 will establish a formal process for the [MBC] to responsively review and confidentially investigate psychotropic medication prescription patterns among California children.”
Background. Psychotropic Medications Prescribed to Foster Youth. According to information obtained from the Child Welfare Indicator Project, over the past fifteen years, the rate of foster youth prescribed psychotropic medication has increased 1,400 percent. Nearly 1 in 4 California foster teens are prescribed psychotropic drugs; of those nearly 60 percent were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects.
A number of factors contribute to the potential for inappropriate psychotropic prescribing practices including:
- A lack of access to effective non-pharmacological interventions and a reliance on medications to quickly control difficult behaviors;
- An inadequate supply of child behavioral health specialists with training in evidence-based, trauma-informed practices;
- Limited clinical knowledge among child welfare case workers about appropriate psychotropic medication use;
- A lack of coordination across providers and child-serving agencies; and,
- Aggressive, effective pharmaceutical marketing and financial incentives that drive prescribing.
In November of 2011, the Centers for Medicare and Medicaid Services (CMS), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Administration for Children and Families (ACF), wrote a joint letter encouraging states to strengthen oversight of psychotropic medication use among the foster youth population.
The MBC and the DHCS Data Use Agreement. In 2014, Senator Ted Lieu, then chair of the Senate Committee on Business, Professions, and Economic Development, sent a letter to the MBC in response to several newspaper articles which asserted that some doctors were prescribing drugs that have not been approved for children, and without reviewing the children's medical records or drug history (San Jose Mercury News, “Drugging Our Kids”, 2014). Senator Lieu requested that the MBC investigate these medical professionals and develop recommendations to minimize dangerous prescribing practices. In response, the MBC and the DHCS adopted a one year trial Data Use Agreement that allows for the sharing of prescriber data in order to identify prescribing patterns of licensees.
This bill would codify the Data Use Agreement allowing the MBC and DHCS to continue identifying licensees who appear to be incorrectly prescribing medication to foster youth and flag them for investigation.
State Auditor Report. The California State Auditor (CSA) is currently engaged in an audit of foster youth and psychotropic medication. It is expected to be released in July or August of 2016. According to information obtained from the CSA website, the audit will select and review four county CWS agencies—two counties identified as having a high prevalence of the use of psychotropic medications for foster children and two counties with a correspondingly low prevalence. The audit will provide independently developed and verified information related to the DSS, DHCS, and a selection of county CWS agencies’ oversight and monitoring of foster children who have been prescribed psychotropic medications, as well as a review of the availability and adequacy of other supportive services, such as mental health and substance abuse counseling. The audit will also determine whether any other states have implemented innovations or oversight systems that have successfully reduced the use of psychotropic medications in foster children or improved their access to non-pharmacological supports, and evaluate whether California could benefit from similar policies or practices.
Other States. Alabama provides a focused mailing to prescribers of any antipsychotics to children under 18, as well as telephone outreach by child psychiatrists to prescribers of antipsychotics to children under age five.
Colorado sends educational alerts and letters to prescribers detailing information about the psychiatric medication utilization of their patients. If post-intervention changes are not observed, follow-up letters and face-to-face meetings with peer consultants are conducted.
Illinois maintains a watch-list of high-risk prescribers, utilizing this data to assess the impact of changes in consent policies on prescriber behaviors.
Michigan created a system whereby child psychiatrists follow-up with prescribing physicians when indicated based on established triggers to review the case and provide consultation.
Missouri uses the Behavioral Pharmacy Management System to analyze prescribing patterns for children and adolescents and send letters to prescribers offering consultation on best prescribing practices. An analysis of this intervention showed a significant reduction in the percentage of outlier prescriptions.
ARGUMENTS IN SUPPORT:
The National Center for Youth Law (sponsor), Children Now, John Burton Foundation, and the Bay Area Youth Center similarly write in their letters of support, “Last year, the [DHCS] and the [MBC] adopted a one-year trial Data Use Agreement that allows for the sharing of prescriber data in order to identify outlying prescribers. Such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing for our children.”
Advokids writes in their letter of support, “We demand high quality, accessible mental health services for foster children and the careful collection of data surrounding psychotropic medications to ensure the physical and emotional safety of our foster youth.”
The Children’s Partnership writes, “TCP strongly supports SB 1174, which will establish a formal process for the MBC to responsively review and confidentially investigate psychotropic medication prescription patterns among California children.”
Consumer Watchdog writes in support, “Over the last year, the legislature has taken important steps to protect the health and safety of foster youth. SB 1174 provides the [MBC] with the information it needs to ensure that physicians’ prescribing patterns are shifting in response to those reforms.”
The Medical Board of California supports the bill if amended and writes, “This bill will further the [MBC’s] mission of consumer protection for a very vulnerable population. The [MBC] is actively working with the author’s office and the sponsors on amendments, as the [MBC] would like a sunset date included in this bill so the [MBC] can determine if the data provided is useful to the [MBC].”
The Pacific Juvenile Defender Center writes in support, “This bill enables the MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children.”
ARGUMENTS IN OPPOSITION:
The Child Academy of Child and Adolescent Psychiatry has an opposed unless amended position and writes, “We would like for this bill to require the MBC to contract with a Board Certified Child and Adolescent Psychiatrist for the purposes of reviewing the data that is proposed; We believe that a more refined data set will help further the goals for this legislation… the LA County Parameters… are a more appropriate starting point for the MBC to review prescribing practices…If the investigation [of a licensee] should not result in disciplinary action, questions regarding whether or not a physician has ever been investigated by the MBC come up often…[W]e believe the envisioned process will have a negative impact on the ability of the Medi-Cal system to recruit and retain high quality providers.”
REGISTERED SUPPORT:
National Center for Youth Law (sponsor)
Advokids
Bay Area Youth Center
Children Now
The Children’s Partnership
Consumer Watchdog
John Burton Foundation
Medical Board of California (support if amended)
Pacific Juvenile Defender Center
REGISTERED OPPOSITION:
Child Academy of Child and Adolescent Psychiatry
Analysis Prepared by: Le Ondra Clark Harvey, Ph.D. / B. & P. / (916) 319-3301
Date of Hearing: June 21, 2016
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SB 1174
Author:(McGuire) – As Amended Ver:June 15, 2016
SENATE VOTE: 36-3
SUBJECT: Medi-Cal: children: prescribing patterns: psychotropic medications.
SUMMARY: Requires the Medical Board of California (MBC) to conduct an analysis of Medi-Cal and managed care prescribing patterns of psychotropic medications to determine if excessive prescribing exists and, if so, to take appropriate action. Adds repeated acts of clearly excessive prescribing psychotropic medications to a minor without a good faith prior examination to the list of cases that MBC must prioritize investigating and prosecuting. Specifically, this bill:
- Requires MBC to conduct on a quarterly basis an analysis of Medi-Cal physicians and their prescribing patterns of psychotropic medications and related services using data provided quarterly by the Department of Health Care Services (DHCS) in collaboration with the Department of Social Services (DSS). Requires that analysis to include, but not be limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. Requires the data concerning psychotropic medications and related services to be shared pursuant to a data sharing agreement meeting the requirements of all applicable state and federal laws and regulations. Requires MBC, DHCS, and DSS to consult and revise the methodology every three years, if determined to be necessary.
- Requires that the data provided to MBC pursuant to 1) above identify prescribers with a pattern of prescribing that includes one or more of the following:
- Prescriptions for any class of psychotropic medication for a child who is five years of age or younger;
- Prescriptions for concurrent administration of two or more antipsychotic medications that exceed 60 days;
- Prescriptions for concurrent administration of three or more psychotropic medications exceeding 60 days; and,
- Prescriptions for a dosage that exceeds the amount recommended for children.
- Requires that the data provided to MBC pursuant to 2) above include the following information on each identified prescriber:
- Prescriber name, specialty, location, and contact information;
- The child’s gender and year of birth;
c) List of the psychotropic medications prescribed, diagnosis, and the medication start and end date;
d) Unit of the medication(s), quantity of the medication(s), the days supply, and prescription fill date: and,
e) The child’s weight.
- Requires that the data provided to MBC pursuant to 1) above include a breakdown as follows:
- Children prescribed psychotropic medications in managed care and fee-for-service settings;
- Children adjudged as dependent children, as specified, and placed in foster care;
- A minor adjudged a ward of the court who has been removed from the physical custody of the parent and placed into foster care; and,
- Children with developmental disabilities.
- Requires that the data provided to MBC as described in 1) and 2) above include total rate and specific age stratifications.
- Requires MBC on a quarterly basis to review the data provided pursuant to 1) through 5) above in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, to conduct an investigation. Requires MBC to disseminate guidelines for prescribing of psychotropic medications to children and adolescents on an annual basis to any prescriber who has been flagged for review. Requires MBC to take appropriate action, as specified, if, after an investigation, MBC concludes that there was a violation of law or excessive prescribing of psychotropic medications inconsistent with the standard of care.
- Requires MBC to report annually to the Legislature, DHCS, and DSS the results of the analysis of data described in 1) through 5) above.
- Adds repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination and medical reason therefor to the list of cases that MBC must prioritize for investigation and prosecution.
EXISTING LAW:
- Provides for the licensure and regulation of physicians and surgeons by MBC pursuant to the Medical Practice Act.
- Requires MBC to take action against a physician who is charged with unprofessional conduct, as specified.
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substance without a good faith prior examination of the patient and medical reason to be handled as a high priority. Prohibits physicians and surgeons from being prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law. (BPC §2220.05)
- Provides that only a juvenile court judicial officer has the authority to make orders regarding the administration of psychotropic medications for a minor who is a dependent of the court. Requires that court authorization for the administration of psychotropic medications be based on a request from a physician, indicating the reasons for the request, a description of the child’s diagnosis and behavior, the expected results of the medication, and a description of any side effects of the medication. Requires the Judicial Council, on or before July 1, 2016, to adopt rules and develop appropriate forms for implementing this requirement. Requires the rules and forms to address all of the following:
- The child and his or her caregiver and Court Appointed Special Advocate (CASA), if any, have an opportunity to provide input on the medications being prescribed;
- Information regarding the child’s overall mental health assessment and treatment plan is provided to the court; and,
- Information regarding the rationale for the proposed medication, provided in the context of past and current treatment efforts, is provided to the court; and,
- Guidance is provided to the court on how to evaluate the request for authorization.
- Requires that the court either approve or deny a physician’s request, pursuant to 4) above, within seven business days of its receipt.
- Establishes a program of public health nursing in the child welfare services (CWS) program that provides health-related case management services from a foster care public health nurse to coordinate with CWS workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications.
- Requires DSS, in consultation with DHCS, and other specified stakeholders to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including paid claims and managed care encounters. Requires DSS to develop training, in consultation DHCS and various other agencies that may be provided to county child welfare social workers and others that addresses the use of psychotropic medications.
FISCAL EFFECT: According to the Senate Appropriations Committee:
1) Ongoing costs up to $280,000 per year for DHCS to analyze prescription drug claims data and compile required information for MBC (General Fund and federal funds). The DHCS’ information technology systems contain prescription drug claims data (when combined with information from DSS on foster care placements) to provide the data required to fulfill the requirements in the bill. DHCS indicates that it will need two additional staff positions to compile the required data, stratify it into the required data categories, and report to MBC.
However, as part of recent efforts to reduce overprescribing of psychotropic medications to foster youth, DHCS has been working with DSS and counties to identify foster youth being prescribed such medications. The Governor’s budget proposal includes an additional permanent position to continue this work. If approved by the Legislature, that new position may be able to also perform some or all of the requirements of this bill as well.
2) Uncertain costs for MBC to review the information provided by DHCS and investigate instances where excessive prescribing may be occurring (Contingent Fund of MBC). According to MBC, its staff is already reviewing data provided by DHCS to look for cases of excessing prescribing. However, to the extent that such data analysis does uncover instances of excessing prescribing, this would lead to increased costs for investigations and potential disciplinary action by MBC. While those instances of excessing prescribing may already be actionable by MBC, under current law and regulation, the data analysis required in the bill makes such investigations more likely to occur.
3) Unknown potential cost savings in the Medi-Cal program due to reduced inappropriate utilization of psychotropic medications by foster youth. To the extent that this bill contributes to ongoing efforts to reduce inappropriate use of those drugs by Medi-Cal beneficiaries, this bill is likely to reduce spending. Ongoing efforts in other states to reduce inappropriate prescribing have substantially reduced the use of these frequently expensive medications. The amount of any decrease in spending that could be attributed to this bill is uncertain, in part because there are several efforts underway by the state and the counties to reduce inappropriate prescribing of psychotropic drugs to foster youth.
COMMENTS:
1) PURPOSE OF THIS BILL. According to the author, this bill stems from a growing and significant concern over the excessive prescribing of psychotropic medication to foster youth in California. It follows a series of hearings held by the California Senate Committees on Health and Human Services regarding the oversight and monitoring of psychotropic medication and mental health services for youth in foster care. Even with the growing attention to this situation, the problem is now more severe than ever and California's 63,000 foster youth are the ones who are suffering the consequences of our state's inaction and lack of oversight over the past 15 years. According to the author, despite our current safeguards in place - the JV-220 process, whereby judges decide what medications and at what dosage are provided to foster youth, over the past fifteen years the rate of foster youth prescribed psychotropic medication has increased 14 fold. The author states that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic (an estimated 75% of them for an off label use) and 36% are prescribed multiple medications.
The author states that, as reported by the San Jose Mercury News, the federal Food and Drug Administration authorizes antipsychotics for children only in cases of severe mental illness, but evidence suggests medical professionals often prescribe them to California foster children for behavior problems. According to the author, California spends more on psychotropic drugs for foster children than on any other kind of medication. In the last decade, the state spent more than $226 million on psychotropic meds for foster children, 72% of total drug spending for this population. Additionally, there are substantial long-term costs of treating side effects associated with these medications. Furthermore, teens in foster care are three and a half times more likely to be prescribed psych medication than their peers who are not in foster care. While the federal Child and Family Services Improvement and Innovation Act of 2011 requires each state to oversee and monitor the use of psychotropic medications, California currently has no requirements to identify those who are over-prescribing medication to foster youth. California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices.
According to the author, this is unacceptable given that it is the state’s responsibility, as the guardian to these children, to monitor the administration of these drugs and to ensure the health and well-being of foster children. In response to legislative pressure, MBC and DHCS adopted a one-year trial Data Use Agreement (DUA) that allows for the sharing of prescriber data in order to identify the outlying prescribers. The author argues that such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing and that this bill establishes a formal, on-going, process for MBC to responsively review and confidentially investigate psychotropic medication prescription patterns outside the standard of care. With this ongoing data sharing agreement with DHCS, MBC will have regular, reliable information to work from instead of depending on the current individual complaint process.
- BACKGROUND. For a number of years, the California Legislature, as well as, the federal government have focused attention on improving conditions for children in the foster care system. Among those concerns is the high rate of prescribing of psychotropic drugs to foster youths. In February 2014, the Senate Human Services Committee and the Select Committee on Mental Health held an informational hearing entitled, “Misuse of Psychotropic Medication in Foster Care: Improving Child Welfare Oversight and Outcomes within the Continuum of Care” that highlighted concerns regarding a statewide trend toward increased prescribing of psychotropic medications. The hearing included testimony indicating that California’s child welfare and children’s mental health systems are over-reliant on psychotropic medication among foster youth and do not effectively manage the provision of such medication leading to unnecessary prescribing, inappropriately high dosages of medication for children, and inappropriate use of multiple medications, and usage occurring at longer durations than appropriate. In response to these concerns, the hearing focused on oversight of individual cases, including court authorization procedures which informed the development of several bills under consideration by the Legislature. Additionally, the hearing highlighted concerns that breakdowns in the provision of effective trauma-informed psychosocial services has led to system-wide failures in treating children and youth who later suffer from trauma-related behavioral health challenges, for which medication is seen as the only available treatment option.
In August 2015, the Senate Human Services and Health Committees held a second hearing entitled “Psychotropic Medication and Mental Health Services for Foster Youth: Seeking Solutions for a Broken System” that focused on system wide standards and oversight tools used by state and local agencies in evaluating the effectiveness of county mental health plans, county child welfare agencies, contracted providers, and individual prescribers in providing access to a broad spectrum of timely, effective, trauma-informed psychosocial services that minimize the need for psychotropic medication.
- Media Reports. A recent series of stories published in the San Jose Mercury News and most recently in the Los Angeles Times, highlighted growing concerns that psychotropic medications have been relied on by California's child welfare and children's mental health systems as a means of controlling, instead of treating, youth who suffer from trauma-related behavioral health challenges. These articles detailed significant challenges in accessing pharmacy benefits claims data held by the DHCS, eventually overcome through a Public Records Act request and lengthy negotiations, and demonstrated that prescribing rates were far higher than had been anticipated by child welfare system experts.
- Court Oversight Mechanisms. SB 543 (Bowen), Chapter 552, Statutes of 1999, mandated that, once a child has been adjudged a dependent of the state, only the court may authorize psychotropic medications for the child, based on a request from a physician that includes the following:
- The reasons for the request;
- A description of the child's diagnosis and behavior;
- The expected results of the medication; and,
- A description of any side effects of the medication.
- The reasons for the request;
Under SB 543, psychotropic medications are defined as those “administered for the purpose of affecting the central nervous system to treat psychiatric disorders or illnesses.” In accordance with SB 543, the Administrative Office of the Courts established a series of court documents generally referred to as “the JV 220,” which includes a statement completed and signed by the prescribing physician that includes the child's diagnosis, relevant medical history, other therapeutic services, the medication to be administered, and the basis for the recommendation.
In addition, a form must be included indicating notice has been provided to the parents or legal guardians, their attorneys of record, the child's attorney of record, the child's guardian ad litem, the child's current caregiver, the child's CASA, if any, and if a child has been determined to be a Native American child, the child's tribe. The procedure for notification varies by county - the responsibility may fall primarily to the child welfare agency, or it may be shared with the juvenile court clerk's office that may be responsible for notifying the attorney and the CASA. Within four court days after notification, a parent or guardian, the child, the attorney for either, the guardian ad litem, or the Indian child's tribe may file an objection to the application. Following this period, the court files a final order.
- Quality Improvement Project. In 2012, DHCS and DSS convened a statewide Quality Improvement Project (QIP) to design, pilot, and evaluate effective practices to improve psychotropic medication use among children and youth in foster care. Three workgroups were established for the project—the Clinical Workgroup, the Data and Technology Workgroup, and the Youth, Family, and Education Workgroup to jointly conduct analysis of child welfare data, develop tools to assist prescribers, pharmacists, and juvenile courts, as well as develop and disseminate training materials and information about psychotropic medications for youths and caregivers.
QIP’s Data and Technology Workgroup released a summary report in December 2014 matching data from CWS/Case Management System and DHCS that detailed fee-for-service and Medi-Cal managed care encounter data pharmacy paid claim records for psychotropic medication for children in foster care during Federal Fiscal Year (FFY) 2012-13. The report found that of 10,557 children (under the age of 21) in California who received at least one paid claim for psychotropic medication during FFY 2012-13, 10,419 (or 98%) of these children were identified as youth in an active out-of-home placement. The report further broke down the data based on age, gender, ethnic group, placement type, responsible agency, time in care, and time in placement.
Although the data produced a wide scope of the breakdown surrounding psychotropic drug prescriptions to foster youth, the report also cautions that there are a number of key analytical considerations when reviewing the data. The report states that the figures presented are not necessarily representative of youth for whom court authorizations for psychotropic medications are required, as it includes youths aged 18-20 years old placed with non-dependent legal guardians and other non-foster care placements as well as youth for whom court authorizations for psychotropic medications are required. In addition, the report states that since only the most recent paid claim for youth under 21 years old was used to examine the case and placement information, this data might not necessarily be reflective of their experience in care or the experiences of youth before and after the period of study. - Guidelines. The QIP’s Clinical Workgroup released a set of guidelines to assist prescribers and caregivers in maintaining compliance with state and county regulations and guidelines pertaining to Medi-Cal funded mental health services and psychotropic prescribing practices for foster homes, group homes, and residential treatment centers. In addition, the guidelines include prescriber and caregiver expectations regarding developing and monitoring treatment plans for behavioral health care, principles for informed consent to medications, and governing medication safety. These guidelines are designed as a statement of best practice for the treatment of children and youth in out-of-home care and include:
- Prescribing standards for psychotropic medication by age group;
- Parameters for psychotropic medication indications, dosing, and monitoring;
- Recommendations to address challenges in the management of complex cases; and,
- Decision “algorithm” to be used by prescribers.
- Prescribing standards for psychotropic medication by age group;
- Efforts in Other States. According to information provided by the author, a number of other states have taken action to address concerns about psychotropic medication. Alabama provides a focused mailing to prescribers of any antipsychotics to children under 18, as well as telephone outreach by child psychiatrists to prescribers of antipsychotics to children under age five. Colorado sends educational alerts and letters to prescribers detailing information about the psychiatric medication utilization of their patients. In Colorado, if post-intervention changes are not observed, follow-up letters and face-to-face meetings with peer consultants are conducted. Illinois maintains a watch-list of high-risk prescribers, utilizing this data to assess the impact of changes in consent policies on prescriber behaviors. Michigan created a system whereby child psychiatrists follow-up with prescribing physicians based on established triggers to review the case and provide consultation. Missouri uses the Behavioral Pharmacy Management System to analyze prescribing patterns for children and adolescents and send letters to prescribers offering consultation on best prescribing practices. An analysis of this intervention showed a significant reduction in the percentage of outlier prescriptions.
- MBC Guidance on Psychotropic Medication. MBC has made available to all licensees on its Website, as well as through an email to its licensee listserv the QIP’s Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care which states that “the use of psychotropic medication for children and youth is considered a non-routine intervention, used under specified circumstances and as only one strategy within a larger, more comprehensive treatment plan to provide for that child's safety and well-being.” MBC’s responsibilities in overseeing their licensees’ prescribing habits of psychotropic medications to foster youth are also a component of an audit currently being conducted by the California State Auditor pertaining to the oversight and monitoring of children in foster care who have been prescribed psychotropic medications.
Strategies were discussed at the October 2015 MBC meeting to help identify physicians who may be inappropriately prescribing psychotropic medications to foster youth as well as identify additional information needed from DHCS and DSS. However, there were concerns raised about the expectations of physicians based on the quality of information in the QIP’s Psychotropic Data Match Report. The MBC has expressed concerns that the data presented in the report may not be sufficient to make a decision as to appropriate prescribing practices for physicians working with foster youth.
MBC has, in the meantime, developed a notification process whereby individuals in the healthcare delivery system for foster youths can directly contact MBC staff if they believe a physician is inappropriately prescribing medication to children in foster care. After a complaint or notification is made, MBC staff will directly contact DSS to obtain all de-identified patient information for the foster child and the prescriber. MBC can then determine whether or not it will need patient records. DSS and the MBC can then obtain these patient records through a court order so that MBC can proceed with an investigation into the prescribing physician. - Data Sharing Efforts. MBC currently has a DUA with DHCS and DSS in order to allow the MBC to receive information that does not breach the confidentiality of a patient. The agreement is based on conversations dating back to 2014 regarding the data needed for the MBC to identify physicians who may be inappropriately prescribing psychotropic medications to foster children. Upon receipt of its first set of data under the DUA, MBC enlisted a pediatric psychiatrist review the data. The physician determined that the information provided through the agreement was not substantive enough to allow MBC to identify instances of any inappropriate prescribing and noted that additional information to assist in this effort would include the diagnosis associated with medication prescribed, the dosage of medication prescribed, the schedule or timing of dosage of medication prescribed and the weight of child or adolescent.
- STATE AUDITOR. The California State Auditor (CSA) is currently engaged in an audit of foster youth and psychotropic medication. It is expected to be released in July or August of this year. According to the CSA Website, the audit will provide independently developed and verified information related to DSS, DHCS, and a selection of county CWS agencies’ oversight and monitoring of foster children who have been prescribed psychotropic medications, as well as a review of the availability and adequacy of other supportive services, such as mental health and substance abuse counseling. The audit will select and review four county CWS agencies—two counties identified as having a high prevalence of the use of psychotropic medications for foster children and two counties with a correspondingly low prevalence. The audit will also determine whether any other states have implemented innovations or oversight systems that have successfully reduced the use of psychotropic medications in foster children or improved their access to non-pharmacological supports, and evaluate whether California could benefit from some of these policies or practices.
- SUPPORT. The National Center for Youth Law (NCYL), the sponsor of this bill, argues that nearly one in four California foster teens are prescribed psychotropic drugs; of those nearly 60% were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects. While the vast majority of doctors prescribing medication are doing so appropriately, California still needs an oversight mechanism (among other reforms including funding robust trauma care services). Currently, California has no system for evaluating the medical soundness of high rates of prescribing; and no way to measure the efficacy of these practices. NCYL noted that last year, DHCS and MBC adopted a one-year trial DUA that allows for the sharing of prescriber data in order to identify outlying prescribers. NCYL argues that such data sharing practices should not be on a one-time basis, but rather an ongoing process for improving the quality of prescribing for our children. This will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children. Advokids, states in support of this bill that it operates the only free statewide telephone hotline providing legal information to anyone concerned about a foster child, and receives a high volume of calls from caregivers who are concerned about the lack of mental health services available to their foster children, many of whom have experienced multiple traumas in their lives. Advokids argues for high quality, accessible mental health services for foster children and the careful collection of data surrounding psychotropic medications to ensure the physical and emotional safety of foster youth and when warranted to investigate physicians who frequently prescribe over the recognized safety parameters for children.
- SUPPORT IF AMENDED. MBC has a support if amended position on this bill. MBC requests additional information (included in the most recent version of this bill) and a sunset date so MBC can determine if the data provided is useful. MBC also has requested that the author amend this bill so that the education component is handled by DHCS since they are the Medi-Cal prescribers and the guidelines were created by DHCS and DSS. MBC notes that any information that can help MBC identify inappropriate prescribing can be utilized as a tool for MBC to use in its complaint and investigation process. However, once a possible inappropriate prescriber is identified, MBC will still have to go through its normal complaint and investigation process.
- OPPOSE UNLESS AMENDED. The California Academy of Child and Adolescent Psychiatry (CACAP) believes that initiating investigations as proposed will ultimately target prescribing physicians who specialize with patients with severe mental health difficulties. CACAP argues that it is unclear how MBC would make a basis for an accusation of unprofessional conduct on the data that is proposed to be provided. Additionally, this process would also discourage physicians from prescribing a psychotropic medication even when, in their professional judgement, it is in the best interest for the child. An investigation by MBC is a significant event. Even if the investigation should not result in disciplinary action, questions regarding whether or not a physician has ever been investigated by MBC come up often in interviews and credentialing reviews. While these red flag aren’t as serious as a filed accusation, we believe the envisioned process will have a negative impact on the ability of the Medi-Cal system to recruit and retain high quality providers for Medi-Cal and Foster youth. The California Medical Association argues that this bill adds another bureaucratic layer to a process that is already highly regulated. Currently, before a prescription for psychotropic medication can be administered to a foster youth, a judge must first approve a court order based on the JV-220 and then a Treatment Authorization Request must be submitted to DHCS to be reviewed by a pharmacist to ensure that the prescription is medically necessary. This process will soon be improved, as required by SB 238 (Mitchell), Chapter 534, Statutes of 2015, with even more information included on the JV-220 to better assist the court.
- PREVIOUS LEGISLATION.
- SB 238 requires certification and training programs for foster parents, child welfare social workers, group home administrators, public health nurses, dependency court judges and court appointed council to include training on psychotropic medication, trauma, and behavioral health, as specified, for children receiving CWS. SB 238 also requires the Judicial Council to amend and adopt rules of court and develop appropriate forms pertaining to the authorization of psychotropic medication for foster youth, on or before July 1, 2016.
- SB 253 (Monning) of 2015 would have revised and strengthened, as juvenile court oversight requirements for administration of psychotropic medications to wards and dependents. SB 253 was placed on the Assembly inactive file.
- SB 484 (Beall), Chapter 540, Statutes of 2015, requires DSS to establish a methodology for identifying group homes that have levels of psychotropic dug utilization warranting additional review, and to inspect identified facilities at least once a year, as specified. The bill permitted DSS to share information and observations with the facility and to require the facility to submit a plan within 30 days to address identified risks, as specified.
- SB 319 (Beall), Chapter 535, Statutes of 2015, expands the duties of the foster care public health nurse to include monitoring and oversight of the administration of psychotropic medication to foster children, as specified.
- SB 238 requires certification and training programs for foster parents, child welfare social workers, group home administrators, public health nurses, dependency court judges and court appointed council to include training on psychotropic medication, trauma, and behavioral health, as specified, for children receiving CWS. SB 238 also requires the Judicial Council to amend and adopt rules of court and develop appropriate forms pertaining to the authorization of psychotropic medication for foster youth, on or before July 1, 2016.
- QUESTIONS AND COMMENTS.
- According to the author and sponsor, the intent of this bill is to protect foster youth. However, as drafted, this bill would apply to all Medi-Cal beneficiaries under age 18 years. The author has agreed to amend this bill so it’s application is limited to foster youth by the following amendments:
On page 5, line 1, insert between “services” and “using”: for individuals described in subparagraph (B) and (C) of paragraph (1) of subdivision (b).
- According to the author and sponsor, the intent of this bill is to protect foster youth. However, as drafted, this bill would apply to all Medi-Cal beneficiaries under age 18 years. The author has agreed to amend this bill so it’s application is limited to foster youth by the following amendments:
On page 5, delete lines 29-30.
- In response to MBC’s concern about providing education, the author proposes the following amendment: On page 4, delete lines 13-16 and replace with:
(b) The [State] Department of Health Care Services shall disseminate guidelines on an annual basis via email to any prescriber who meets the data requirement threshold for prescribing of psychotropic medications to children and adolescents established in subdivision (c) of Section 14028 of the Welfare and Institutions Code.
- Information about activities in other states that the author has provided to the Committee suggests that individual educational outreach including telephone calls from child psychiatrists, face-to-face meetings, and consultations on best prescribing practices. Should educational endeavors such as these be included in this bill?
- Information about activities in other states that the author has provided to the Committee suggests that individual educational outreach including telephone calls from child psychiatrists, face-to-face meetings, and consultations on best prescribing practices. Should educational endeavors such as these be included in this bill?
- DOUBLE REFERRAL. This bill has been double-referred. Should this bill pass out of this Committee, it will be referred to the Assembly Business and Professions Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
National Center for Youth Law (sponsor)
Advokids
Bay Area Youth Center
Family Voices of California
Kids in Common, Planned Parenthood Mar Monte
Madera County Department of Social Services
Peers Envisioning and Engaging in Recovery Services
California Youth Connection
Consumer Attorneys of California
Consumer Watchdog
First Focus Campaign for Children
John Burton Foundation
Therapists for Peace and Justice
Western Center on Law and Poverty
Woodland Community College Foster and Kinship Care Education
Youth Law Center
1 Individual
Opposition
California Academy of Child & Adolescent Psychiatry
California Medical Association
Analysis Prepared by: John Gilman / HEALTH / (916) 319-2097
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB |
THIRD READING
Bill No: SB 1174
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 4/11/16
AYES: Hill, Berryhill, Block, Galgiani, Hernandez, Jackson, Mendoza, Wieckowski
NO VOTE RECORDED: Bates
SENATE APPROPRIATIONS COMMITTEE: 6-0, 5/27/16
AYES: Lara, Bates, Beall, Hill, McGuire, Mendoza
NO VOTE RECORDED: Nielsen
SOURCE: National Center for Youth
DIGEST: This bill adds the following causes of action to the Medical Board of California’s (MBC) list of priority cases for investigation and prosecution: “repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason;” and requires the Department of Health Care Services (DHCS) to provide quarterly data to MBC on psychotropic medications prescribed to foster youth and requires the MBC to provide quarterly reports on violations of the law or standards of care.
Existing law:
- Provides for the licensure and regulation of physicians and surgeons by the MBC pursuant to the Medical Practice Act (Act). (Business and Professions Code (BPC) Sections 2000 et seq.)
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substances without a good faith prior examination of the patient and medical reason to be handled as a high priority. Specifies that physicians and surgeons shall not be prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law. (BPC § 2220.05)
- Provides that only a juvenile court judicial officer shall have authority to make orders regarding the administration of psychotropic medications for a minor who has been adjudged a dependent of the court and removed from the physical custody of his or her parent. (Welfare and Institutions Code (WIC) § 369.5)
- Establishes a program of public health nursing in the child welfare services program that provides health-related case management services from a foster care public health nurse to coordinate with child welfare service workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications. Requires public health nurses to receive training related to psychotropic medications, as specified.
(WIC § 16501.3) - Requires Department of Social Services (DSS), in consultation with DHCS and other specified stakeholders, to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including authorized medications, pharmacy data including the quantity and dose, other available information regarding psychosocial interventions and incidents of polypharmacy. (WIC § 16501.4)
This bill:
- Adds “repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor” to the list of cases for which MBC must prioritize its investigative and prosecutorial resources.
- Requires DHCS, in collaboration with DSS, to provide quarterly data to MBC that includes, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. Specifies that data provided to MBC shall include a breakdown by population of the following for birth to 5 years old, 6 to 11 years old and 12-17 years old:
- Children prescribed psychotropic medications in managed care and fee-for-service settings.
- Children adjudged as dependent children and placed in foster care.
- Children in juvenile halls and children placed in ranches, camps, or other facilities.
- A minor adjudged a ward of the court who has been removed from the physical custody of the parent and placed into foster care.
- Children with developmental disabilities.
- Requires MBC to review the information provided by DHCS on a quarterly basis in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, to conduct an investigation. Requires MBC to take disciplinary action as appropriate if, after an investigation, MBC concludes that there was a violation of law, including a conclusion that there was excessive prescribing of psychotropic medications inconsistent with the standard of care. Requires MBC to provide a quarterly report to the Legislature, DHCS and DSS.
Background
Psychotropic Medication. According to background information from recent Senate hearings on this issue, concern over the use of psychotropic medications among children has been well-documented in research journals and the mainstream media for more than a decade. The category of psychotropic medication is fairly broad, intending to treat symptoms of conditions ranging from attention deficit hyperactivity disorder (ADHD) to childhood schizophrenia. Some of the drugs used to treat these conditions are U.S. Food and Drug Administration (FDA) approved, including stimulants like Ritalin for ADHD, however only about 31 percent of psychotropic medications have been approved by the FDA for use in children or adolescents. It is estimated that more than 75 percent of the prescriptions written for psychiatric illness in this population are "off label" in usage, meaning they have not been approved by the FDA for the prescribed use, though the practice is legal and common across all manner of pharmaceuticals.
Anti-psychotic medications, used to treat more severe mental health conditions, include powerful brand-name drugs such as Haldol, Risperdal, Abilify, Seroquel and Zyprexa. They have very limited approval by the FDA for pediatric use beyond rare and severe conduct problems that are resistant to other forms of treatment, such as Tourette's syndrome, behavioral symptoms associated with autistic disorder, childhood schizophrenia, and bipolar disorder. However, the off-label use of these anti-psychotics among children is high, particularly among foster children. According to a study published in 2011, children who took antipsychotic medications were likely to suffer ill health effects including "cardio metabolic and endocrine side-effects" as well as significant weight gain. The authors recommended that collaboration between child and adolescent psychiatrists, general practitioners and pediatricians is essential to "reduce the likelihood of premature cardiovascular morbidity and mortality."
Compounding the potential for unintended side effects is the use of combinations of psychotropic medications, which foster youth are particularly likely to be prescribed, despite limited evidence of clinical efficacy. Protecting the health and well-being of children who are taking one or more psychotropic medications requires extensive and ongoing health and metabolic screenings to identify potential adverse effects quickly, however in practice many children many fail to receive ongoing screenings and adverse effects may go undetected causing permanent injury or death.
Medical Board Efforts to Provide Guidance to Licensees on Prescribing. The MBC made available to all licensees on its Web site, as well as through an e-mail to its licensee listserv, the DHCS and DSS’s statewide Quality Improvement Project (QIP) Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care, which states that “the use of psychotropic medication for children and youth is considered a non-routine intervention, used under specified circumstances and as only one strategy within a larger, more comprehensive treatment plan to provide for that child's safety and well-being”. MBC’s responsibilities in overseeing their licensees’ prescribing habits of psychotropic medications to foster youth are also a component of an audit currently being conducted by the California State Auditor pertaining to the oversight and monitoring of children in foster care who have been prescribed psychotropic medications.
At the October 2015 MBC meeting, the Board discussed strategies to help identify physicians who may be inappropriately prescribing psychotropic medications to foster youth as well as identify additional information needed from DHCS and DSS. However, there were concerns raised about the expectations of physicians based on the quality of information in the QIP’s Psychotropic Data Match Report. The MBC has expressed concerns that the data presented in the report may not be sufficient to make a decision as to appropriate prescribing practices for physicians working with foster youth.
The Board has, in the meantime, developed a notification process whereby individuals in the healthcare delivery system for foster youths can directly contact MBC staff if they believe a physician is inappropriately prescribing medication to children in foster care. After a complaint or notification is made, MBC staff will directly contact DSS to obtain all de-identified patient information for the foster child and the prescriber. The Board can then determine whether or not it will need patient records. DSS and the MBC can then obtain these patient records through a court order so that the Board can proceed with an investigation into the prescribing physician.
Data Sharing Efforts. MBC currently has a data user agreement (DUA) with DHCS and DSS in order to allow the MBC to receive information that does not breach the confidentiality of a patient. The agreement is based on conversations dating back to 2014 regarding the data needed for the MBC to identify physicians who may be inappropriately prescribing psychotropic medications to foster children. Upon receipt of its first set of data under the DUA, MBC enlisted a pediatric psychiatrist to review the data. The physician determined that the information provided through the agreement was not substantive enough to allow MBC to identify instances of any inappropriate prescribing and noted that additional information to assist in this effort would include the diagnosis associated with medication prescribed, the dosage of medication prescribed, the schedule or timing of dosage of medication prescribed and the weight of child or adolescent.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
According to the Senate Appropriations Committee:
- Ongoing costs up to $280,000 per year for the DHCS to analyze prescription drug claims data and compile required information for the MBC (General Fund and federal funds). The DHCS’s information technology systems contain prescription drug claims data (when combined with information from the DSS on foster care placements) to provide the data required to fulfill the requirements in the bill. DHCS indicates that it will need two additional staff positions to compile the required data, stratify it into the required data categories, and report to the MBC.
However, as part of recent efforts to reduce overprescribing of psychotropic medications to foster youth, the DHCS has been working with the DSS and counties to identify foster youth being prescribed such medications. The Governor’s budget proposal includes an additional permanent position to continue this work. If approved by the Legislature, that new position may be able to also perform some or all of the requirements of this bill as well.
- Uncertain costs for the MBC to review the information provided by the DHCS and investigate instances where excessive prescribing may be occurring (Contingent Fund of the MBC). According to the MBC, its staff are already reviewing data provided by the DHCS to look for cases of excessing prescribing. However, to the extent that such data analysis does uncover instances of excessing prescribing, this would lead to increased costs for investigations and potential disciplinary action by the MBC. While those instances of excessing prescribing may already be actionable by the MBC under current law and regulation, the data analysis required in the bill makes such investigations more likely to occur.
- Unknown potential cost savings in the Medi-Cal program due to reduced inappropriate utilization of psychotropic medications by foster youth. To the extent that this bill contributes to ongoing efforts to reduce inappropriate use of those drugs by Medi-Cal beneficiaries, the bill is likely to reduce spending. Ongoing efforts in other states to reduce inappropriate prescribing have substantially reduced the use of these frequently expensive medications. The amount of any decrease in spending that could be attributed to this bill is uncertain, in part because there are several efforts underway by the state and the counties to reduce inappropriate prescribing of psychotropic drugs to foster youth.
National Center for Youth (source)
Bay Area Youth Center
California Youth Connection
Consumer Attorneys of California
Consumer Watchdog
Family Voices of California
First Focus Campaign for Children
John Burton Foundation
Kids in Common, a program of Planned Parenthood Mar Monte
Madera County Department of Social Services
Peers Envisioning and Engaging in Recovery Services
Therapists for Peace and Justice
Woodland Community College Foster and Kinship Care Education
Youth Law Center
One individual
OPPOSITION: (Verified 5/27/16)
California Medical Association
California Academy of Child and Adolescent Psychiatry
ARGUMENTS IN SUPPORT: Numerous groups such as the Youth Law Center, Consumer Attorneys of California, and First Focus Campaign for Children support this bill, citing the frequency of psychotropic drug prescription among foster youth. These groups call for an appropriate oversight mechanism that can help identify outlying prescribers. They argue that this bill will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children.
ARGUMENTS IN OPPOSITION: The California Medical Association (CMA) is concerned that this bill adds another bureaucratic layer to a process that is already highly regulated and are concerned that the bill will delay or prevent some youth from receiving appropriate treatments as well as discouraging physicians from working within the Medi-Cal program. CMA notes that because the medical records are protected, the data that provided to the MBC will provide an incomplete picture without the underlying medical records which can only be obtained through a court order or if the patient waives confidentiality. CMA believes that investigations will target physicians working specifically within the Medi-Cal system or mental health professionals who specialize with patients with severe mental health difficulties. CMA cites the example of a psychiatrist who works exclusively in Juvenile Hall or group homes as potentially having a much higher rate of psychotropic prescriptions to children than a psychiatrist providing services to the general population which will trigger that physician being investigated.
CMA believes that this bill has the potential to discourage physicians from working within the Medi-Cal program which is already suffering from access problems as well as cause some physicians not to prescribe psychotropic medications even if they feel it is an appropriate treatment option.
CMA is requesting an amendment to ensure that educational outreach be required before MBC could initiate an investigation based on the data received from DHCS. They suggest that the guidelines could be a useful tool as the centerpiece of educational outreach.
5/28/16 16:46:01
**** END ****
SENATE COMMITTEE ON
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
SB 1174 (McGuire) - Medi-Cal: children: prescribing patterns: psychotropic medications
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
SB 1174 would require the Department of Health Care Services to provide quarterly data to the Medical Board related to the prescribing of psychotropic medications through the Medi-Cal program to foster youth. The bill would require the Medical Board to review the data to determine if there is excessing prescribing. The bill would require the Medical Board to prioritize cases of excessive prescribing of psychotropic medications to minors for investigation.
Fiscal Impact:
- Ongoing costs up to $280,000 per year for the Department of Health Care Services to analyze prescription drug claims data and compile required information for the Medical Board (General Fund and federal funds). The Department’s information technology systems contain prescription drug claims data (when combined with information from the Department of Social Services on foster care placements) to provide the data required to fulfill the requirements in the bill. The Department indicates that it will need two additional staff positions to compile the required data, stratify it into the required data categories, and report to the Medical Board.
However, as part of recent efforts to reduce overprescribing of psychotropic medications to foster youth, the Department has been working with the Department of Social Services and counties to identify foster youth being prescribed such medications. The Governor’s budget proposal includes an additional permanent position to continue this work. If approved by the Legislature, that new position may be able to also perform some or all of the requirements of this bill as well.
- Uncertain costs for the Medical Board of California to review the information provided by the Department of Health Care Services and investigate instances where excessive prescribing may be occurring (Contingent Fund of the Medical Board of California). According to the Medical Board, its staff are already reviewing data provided by the Department to look for cases of excessing prescribing. However, to the extent that such data analysis does uncover instances of excessing prescribing, this would lead to increased costs for investigations and potential disciplinary action by the Medical Board. While those instances of excessing prescribing may already be actionable by the Medical Board under current law and regulation, the data analysis required in the bill makes such investigations more likely to occur.
- Unknown potential cost savings in the Medi-Cal program due to reduced inappropriate utilization of psychotropic medications by foster youth. To the extent that this bill contributes to ongoing efforts to reduce inappropriate use of those drugs by Medi-Cal beneficiaries, the bill is likely to reduce spending. Ongoing efforts in other states to reduce inappropriate prescribing have substantially reduced the use of these frequently expensive medications. The amount of any decrease in spending that could be attributed to this bill is uncertain, in part because there are several efforts underway by the state and the counties to reduce inappropriate prescribing of psychotropic drugs to foster youth.
Background:
Under current law, only a juvenile court judicial officer may order the administration of psychotropic medications for a minor who is a dependent of the court (i.e. a foster youth). Foster youth are categorically eligible for Medi-Cal benefits and hence Medi-Cal provides coverage for those psychotropic medications.
Psychotropic medications are intended to treat a variety of mental health conditions. While many patients benefit from the use of psychotropic medications, there are often serious side effects, particularly when taken in combination. In general, the use of psychotropic medications on children and adolescents is “off label” meaning that those drugs have not been specifically approved for use in children or adolescents. According to the Department of Social Services, about 11% of foster youth under age 17 are authorized to receive psychotropic medications. Concerns have been raised by advocates for foster youth that many foster youth are being prescribed these medications to sedate them, rather than to appropriately address their mental health and behavioral health needs.
In response to concerns about the high rate of psychotropic drugs administered to foster youth, the Department of Health Care Services expanded its existing policy requiring treatment authorization requests for psychotropic drugs for Medi-Cal beneficiaries. Previously, the Department required a prior treatment authorization request before Medi-Cal would authorize psychotropic drugs for Medi-Cal beneficiaries under age six. In October 2014, the Department expanded this requirement for children and adolescents up to age 17. The treatment authorization request process allows for emergency prescriptions while the request is under review. In addition, in April 2015 the Department of Health Care Services and the Department of Social Services released guidelines for the use of psychotropic medications in foster youth.
Proposed Law:
SB 1174 would require the Department of Health Care Services to provide quarterly data to the Medical Board related to prescribing of psychotropic medications through the Medi-Cal program to foster youth.
The bill would require the Medical Board to review the data to determine if there is excessing prescribing. If instances of excessing prescribing are found, the bill would require the Medical Board to take disciplinary action against the prescribing physician. The Medical Board would be required to report quarterly to the Legislature on the results of its analysis.
The bill would require the Medical Board to prioritize cases of excessive prescribing of psychotropic medications to minors for investigation.
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2015 - 2016 Regular
Bill No: SB 1174 Hearing Date: April 11, 2016
Author: | McGuire | ||
Version: |
| ||
Urgency: | Fiscal: | ||
Consultant: | |||
Subject: Medi-Cal: children: prescribing patterns: psychotropic medications
SUMMARY:
Adds to the list of cases that the Medical Board of California (MBC) prioritizes for its investigative and prosecutorial resources, the following: “Repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason.” Requires the Department of Health Care Services (DHCS) to provide quarterly data to MBC related to prescriptions of psychotropic medications for foster youth and requires the board to provide quarterly reports after reviewing the information provided by DHCS and determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist.
Existing law:
- Provides for the licensure and regulation of physicians and surgeons by the Medical Board of California (MBC) pursuant to the Medical Practice Act (Act). (Business and Professions Code (BPC) § 2000 et. seq.)
- Provides that the MBC shall take action against a physician who is charged with unprofessional conduct, as specified. (BPC § 2234)
- Requires MBC to prioritize its investigative and prosecutorial resources to ensure that physicians and surgeons representing the greatest threat of harm are identified and disciplined expeditiously. Requires cases involving excessive prescribing, furnishing or administering of controlled substances, or repeated acts of prescribing, dispensing or furnishing of controlled substance without a good faith prior examination of the patient and medical reason to be handled as a high priority. States that physicians and surgeons shall not be prosecuted for excessive prescribing when prescribing, furnishing or administering controlled substances for intractable pain as authorized under current law. (BPC §2220.05)
- Provides MBC with the authority to issue a probationary physician's and surgeon's certificate to an applicant subject to terms and conditions, including, but not limited to practice limited to a supervised, structured environment, continuing medical or psychiatric treatment, ongoing participation in a specified rehabilitation program, or abstention from the use of alcohol or drugs. (BPC §2221)
- Authorizes a physician and surgeon to prescribe for, or dispense or administer to, a person under his or her treatment for a medical condition dangerous drugs or prescription controlled substances for the treatment of pain or a condition causing pain, including, but not limited to, intractable pain. Provides that a physician and surgeon shall not be subject to disciplinary action for prescribing, dispensing, or administering dangerous drugs or prescription controlled substances according to certain requirements. Authorizes MBC to take any action against a physician and surgeon who violates laws related to inappropriate prescribing. Provides that a physician and surgeon shall exercise reasonable care in determining whether a particular patient or condition, or the complexity of a patient’s treatment, including, but not limited to, a current or recent pattern of drug abuse, requires consultation with, or referral to, a more qualified specialist.
(BPC § 2241.5) - Provides that only a juvenile court judicial officer shall have authority to make orders regarding the administration of psychotropic medications for a minor who has been adjudged a dependent of the court and removed from the physical custody of his or her parent. Requires the Judicial Council to adopt rules of court and develop appropriate forms. (Welfare and Institutions Code (WIC) § 369.5)
- Provides for the development of a statewide coordinated training program designed specifically to meet the needs of county child protective services social workers, agencies under contract with county welfare departments to provide child welfare services, and persons defined as a mandated reporter pursuant to the Child Abuse and Neglect Reporting Act. (WIC §16206)
- Establishes a program of public health nursing in the child welfare services program that provides health-related case management services from a foster care public health nurse to coordinate with child welfare service workers to provide health care services to children in foster care. Includes among the duties of public health nurses the monitoring and oversight of psychotropic medications. Requires public health nurses to receive training related to psychotropic medications, as specified. (WIC § 16501.3)
- Requires Department of Social Services (DSS), in consultation with DHCS, and other specified stakeholders to develop county-specific monthly reports that describe each child for whom one or more psychotropic medications have been paid for under Medi-Cal, including authorized medications, pharmacy data including the quantity and dose of medications, other available information regarding psychosocial interventions and incidents of polypharmacy. Requires DSS to develop training, in consultation with DHCS, the Judicial Council, the County Welfare Directors Association of California, the County Behavioral Health Directors Association of California, the Chief Probation Officers of California, and stakeholders, that may be provided to county child welfare social workers, probation officers, courts hearing dependency or delinquency cases, children’s attorneys, children’s caregivers, court-appointed special advocates, and other relevant staff who work with children under the jurisdiction of the juvenile court that addresses the authorization, uses, risks, benefits, assistance with self-administration, oversight, and monitoring of psychotropic medications, trauma, and substance use disorder and mental health treatments, including how to access those treatments
(WIC § 16501.4)
This bill:
- Adds repeated acts of clearly excessive prescribing, furnishing, or administering psychotropic medications to a minor without a good faith prior examination of the patient and medical reason therefor to the list of cases that MBC shall prioritize its investigative and prosecutorial resources.
- Requires DHCS to provide quarterly data to MBC, in collaboration with DSS that includes, but is not limited to, the child welfare psychotropic medication measures and the Healthcare Effectiveness Data and Information Set measures related to psychotropic medications. Specifies that data provided to MBC shall include a breakdown by population of the following and including rate and age stratifications for birth to 5 years old, 6 to 11 years old and 12-17 years old:
- Children prescribed psychotropic medications in managed care and fee-for-service settings.
- Children adjudged as dependent children and placed in foster care.
- Children in juvenile halls and children placed in ranches, camps, or other facilities.
- A minor adjudged a ward of the court who has been removed from the physical custody of the parent and placed into foster care.
- Children with developmental disabilities.
- Requires MBC to review the information provided by DHCS on a quarterly basis in order to determine if any potential violations of law or excessive prescribing of psychotropic medications inconsistent with the standard of care exist and, if warranted, to conduct an investigation. Requires MBC to take disciplinary action as appropriate if, after an investigation, MBC concludes that there was a violation of law, including a conclusion that there was excessive prescribing of psychotropic medications inconsistent with the standard of care. Requires MBC to provide a quarterly report to the Legislature, DHCS and DSS.
FISCAL EFFECT: Unknown. This bill is keyed “fiscal” by Legislative Counsel.
COMMENTS:
- Purpose. This bill is sponsored by the National Center for Youth and stems from a series of hearings held by the California State Senate Committees on Health and Human Services regarding the oversight and monitoring of psychotropic medication and mental health services for youth in foster care.
According to the Author, over the past fifteen years, the rate of foster youth prescribed psychotropic medication has increased 1,400 percent. Nearly 1 in 4 California foster teens are prescribed psychotropic drugs; of those nearly 60 percent were prescribed an anti-psychotic – the powerful drug class most susceptible to debilitating side effects. The Author states that while the Child and Family Services Improvement and Innovation Act of 2011 requires each state to oversee and monitor the use of psychotropic medications with children in care, there are currently no requirements to identify those who are over-prescribing medication to foster youth. According to the Author, the state has not been monitoring over-prescribing because the data collection and data sharing system is not in place but that given the state’s responsibility to monitor the administration of these drugs and to ensure the health and well-being of foster children, we should implement a process that provides the appropriate oversight for these powerful medications. The Author states that by establishing a formal process for MBC to responsively review and confidentially investigate psychotropic medication prescription patterns among California children, the bill brings our state in line with standard oversight practice in Washington, Illinois, and Ohio, whose initiatives have shown a 25 percent decrease in dangerous prescribing practices and have improved the overall prescription frequency for medically acceptable reasons.
- Background.
- Psychotropic Medication. According to background information from recent Senate hearings on this issue, concern over the use of psychotropic medications among children has been well-documented in research journals and the mainstream media for more than a decade. The category of psychotropic medication is fairly broad, intending to treat symptoms of conditions ranging from attention deficit hyperactivity disorder (ADHD) to childhood schizophrenia. Some of the drugs used to treat these conditions are U.S. Food and Drug Administration (FDA)-approved, including stimulants like Ritalin for ADHD, however only about 31 percent of psychotropic medications have been approved by the FDA for use in children or adolescents. It is estimated that more than
75 percent of the prescriptions written for psychiatric illness in this population are "off label" in usage, meaning they have not been approved by the FDA for the prescribed use, though the practice is legal and common across all manner of pharmaceuticals.
Anti-psychotic medications, used to treat more severe mental health conditions, include powerful brand-name drugs such as Haldol, Risperdal, Abilify, Seroquel and Zyprexa. They have very limited approval by the FDA for pediatric use beyond rare and severe conduct problems that are resistant to other forms of treatment, such as Tourette's syndrome, behavioral symptoms associated with autistic disorder, childhood schizophrenia, and bipolar disorder. However, the off-label use of these anti-psychotics among children is high, particularly among foster children. According to a study published in 2011, children who took antipsychotic medications were likely to suffer ill health effects including "cardio metabolic and endocrine side-effects" as well as significant weight gain. The authors recommended that collaboration between child and adolescent psychiatrists, general practitioners and pediatricians is essential to "reduce the likelihood of premature cardiovascular morbidity and mortality."
Compounding the potential for unintended side effects is the use of combinations of psychotropic medications, which foster youth are particularly likely to be prescribed, despite limited evidence of clinical efficacy. Protecting the health and well-being of children who are taking one or more psychotropic medication requires extensive and ongoing health and metabolic screenings to identify potential adverse effects quickly, however in practice many children many fail to receive ongoing screenings and adverse effects may go undetected causing permanent injury or death.
- Media Reports. A recent series of stories published in the San Jose Mercury News and most recently in the Los Angeles Times, highlighted growing concerns that psychotropic medications have been relied on by California's child welfare and children's mental health systems as a means of controlling, instead of treating, youth who suffer from trauma-related behavioral health challenges. The series detailed significant challenges in accessing pharmacy benefits claims data held by the DHCS, eventually overcome through a Public Records Act request and lengthy negotiations, and demonstrated that prescribing rates were far higher than had been anticipated by child welfare system experts.
- Court Oversight Mechanisms. SB 543 (Bowen, Chapter 552, Statutes of 1999) mandated that, once a child has been adjudged a dependent of the state, only the court may authorize psychotropic medications for the child, based on a request from a physician that includes the following:
- The reasons for the request;
- A description of the child's diagnosis and behavior;
- The expected results of the medication;
- A description of any side effects of the medication.
Under the statute, psychotropic medications are defined as those “administered for the purpose of affecting the central nervous system to treat psychiatric disorders or illnesses. These medications include, but are not limited to, anxiolytic agents, antidepressants, mood stabilizers, antipsychotic medications, anti-Parkinson agents, hypnotics, medications for dementia, and psychostimulants.”
In accordance with this statute, the Administrative Office of the Courts established a series of court documents generally referred to as “the JV 220”, which includes a statement completed and signed by the prescribing physician that includes the child's diagnosis, relevant medical history, other therapeutic services, the medication to be administered, and the basis for the recommendation.
In addition, a form must be included indicating notice has been provided to the parents or legal guardians, their attorneys of record, the child's attorney of record, the child's guardian ad litem, the child's current caregiver, the child's Court Appointed Special Advocate, if any, and if a child has been determined to be an Indian child, the Indian child's tribe. The procedure for notification varies by county - the responsibility may fall primarily to the child welfare agency, or it may be shared with the juvenile court clerk's office that may be responsible for notifying the attorney and the Court Appointed Special Advocate.
Within four court days after notification, a parent or guardian, the child, the attorney for either, the guardian ad litem, or the Indian child's tribe may file an objection to the application. Following this period, the court files a final order.
- Oversight Concerns. Stakeholders have expressed concerns about the efficacy of oversight mechanisms, given that in many counties the court lacks access to medical experts to assist in evaluating medical information. Child welfare advocates and clinicians reported that in many instances a prescribing physician who fills out the JV 220 form may not have a history of treating the child, and thus may not be aware of prior medications or alternative treatments that have (or have not) been tried. Such information is frequently left blank on the JV 220. Additionally the California Drug Use Review recently found that fewer than four in ten children had received the required baseline laboratory screenings prior to being administered a psychotropic medication. In theory, a health and education passport - a paper file of the youth's medical history - is supposed to be provided to a new caregiver, who might provide important information to a prescribing physician; however it is common for a child to move between placements without the requisite records, leaving the foster parent also unaware of the child's medical history.
The JV 220 form offers little opportunity for input from the community of representatives and caregivers involved with the youth except to offer a short window of opportunity to formally object. Furthermore, the form does not include information related to baseline or ongoing screening, it does not require consideration of alternative treatments (though it provides a field inquiring about them), nor does it offer substantive opportunities for relevant parties to weigh in with important information that may be worthy of consideration by the court.
In 2012, DHCS and DSS convened a statewide Quality Improvement Project (QIP) to design, pilot, and evaluate effective practices to improve psychotropic medication use among children and youth in foster care. Three workgroups were established for the project—the Clinical Workgroup, the Data and Technology Workgroup, and the Youth, Family, and Education Workgroup to jointly conduct analysis of child welfare data, develop tools to assist prescribers, pharmacists, and juvenile courts, as well as develop and disseminate training materials and information about psychotropic medications for youths and caregivers.
QIP’s Data and Technology Workgroup released a summary report in December 2014 matching data from Child Welfare Services/Case Management System (CWS/CMS) and DHCS that detailed fee-for-service and Medi-Cal managed care encounter data pharmacy paid claim records for psychotropic medication for children in foster care during Federal Fiscal Year (FFY) 2012-13. The report found that of 10,557 children (under the age of 21) in California who received at least one paid claim for psychotropic medication during FFY 2012-13, 10,419 (or 98 percent) of these children were identified as youth in an active out-of-home placement. The report further broke down the data based on age, gender, ethnic group, placement type, responsible agency, time in care, and time in placement.
Although the data produced a wide scope of the breakdown surrounding psychotropic drug prescriptions to foster youth, the report also cautions that there are a number of key analytical considerations when reviewing the data. The report states that the figures presented are not necessarily representative of youth for whom court authorizations for psychotropic medications are required, as it includes youths aged 18-20 years old placed with non-dependent legal guardians and other non-foster care placements as well as youth for whom court authorizations for psychotropic medications are required. In addition, the report states that since only the most recent paid claim for youth under 21 years old was used to examine the case and placement information, this data might not necessarily be reflective of their experience in care or the experiences of youth before and after the period of study.
- Guidelines. The QIP’s Clinical Workgroup released a set of guidelines to assist prescribers and caregivers in maintaining compliance with State and county regulations and guidelines pertaining to Medi-Cal funded mental health services and psychotropic prescribing practices for foster homes, group homes, and residential treatment centers. In addition, the guidelines include prescriber and caregiver expectations regarding developing and monitoring treatment plans for behavioral health care, principles for informed consent to medications, and governing medication safety.
These guidelines are designed as a statement of best practice for the treatment of children and youth in out-of-home care and include:
- Prescribing standards for psychotropic medication by age group;
- Parameters for psychotropic medication indications, dosing, and monitoring;
- Recommendations to address challenges in the management of complex cases; and
- Decision “algorithm” to be used by prescribers.
- Efforts in Other States. According to information provided by the Author, a number of other states have taken action to address concerns about psychotropic medication. Alabama provides a focused mailing to prescribers of any antipsychotics to children under 18, as well as telephone outreach by child psychiatrists to prescribers of antipsychotics to children under age five. Colorado sends educational alerts and letters to prescribers detailing information about the psychiatric medication utilization of their patients. In Colorado, if post-intervention changes are not observed, follow-up letters and face-to-face meetings with peer consultants are conducted. Illinois maintains a watch-list of high-risk prescribers, utilizing this data to assess the impact of changes in consent policies on prescriber behaviors. Michigan created a system whereby child psychiatrists follow-up with prescribing physicians based on established triggers to review the case and provide consultation. Missouri uses the Behavioral Pharmacy Management System to analyze prescribing patterns for children and adolescents and send letters to prescribers offering consultation on best prescribing practices. An analysis of this intervention showed a significant reduction in the percentage of outlier prescriptions.
- Medical Board Efforts to Provide Guidance to Licensees on Prescribing.
MBC utilizes guidelines for prescribing controlled substances for pain that the board established. In 1994, MBC unanimously adopted a policy statement entitled “Prescribing Controlled Substances for Pain” stemming studies and discussions about controlled substances which was designed to provide guidance to improve prescriber standards for pain management, while simultaneously undermining opportunities for drug diversion and abuse. The guidelines outlined appropriate steps related to a patient's examination, treatment plan, informed consent, periodic review, consultation, records, and compliance with controlled substances laws. Guidelines are used by physicians as well as MBC in its regulation of licensees.
Subsequent to MBC's 1994 action, legislation that took effect in 2002 (AB 487, Aroner, Chapter 518, Statutes of 2001) that created a task force to revisit the 1994 guidelines to develop standards assuring competent review in cases concerning the under-treatment and under-medication of a patient's pain and also required continuing education courses for physicians in the subjects of pain management and the treatment of terminally ill and dying patients. As a result, the task force amended the guidelines from referencing only intractable pain to all kinds of pain.
Guidelines were further updated following the passage of AB 2198 in 2006 (Houston, Chapter 350, Statutes of 2006), clarifying that health care professionals with a medical basis, including the treatment of pain, for prescribing, furnishing, dispensing, or administering dangerous drugs or prescription controlled substances, may do so without being subject to disciplinary action or prosecution. AB 2198 stemmed from MBC's efforts to better reflect the current state of treating pain, as well as the current manner of investigating and disciplining physicians who treat patients with pain, who often require large quantities of medication.
MBC currently encourages all licensees to consult the policy statement and Guidelines for Prescribing Controlled Substances for Pain. MBC also highlights that while it is lawful under both federal and California law to prescribe controlled substances for the treatment of pain, including intractable pain, there are limitations on the prescribing of controlled substances to or for patients for the treatment of chemical dependency. MBC expects that a licensee follow the same standard of care when prescribing and/or administering a narcotic controlled substance to a “known addict” patient as he or she would for any other patient.
MBC has made available to all licensees on its website as well as through an email to its licensee listserv the QIP’s Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care which states that “the use of psychotropic medication for children and youth is considered a non-routine intervention, used under specified circumstances and as only one strategy within a larger, more comprehensive treatment plan to provide for that child's safety and well-being”. MBC’s responsibilities in overseeing their licensees’ prescribing habits of psychotropic medications to foster youth are also a component of an audit currently being conducted by the California State Auditor pertaining to the oversight and monitoring of children in foster care who have been prescribed psychotropic medications.
At the October 2015 MBC meeting, the Board discussed strategies to help identify physicians who may be inappropriately prescribing psychotropic medications to foster youth as well as identify additional information needed from DHCS and DSS. However, there were concerns raised about the expectations of physicians based on the quality of information in the QIP’s Psychotropic Data Match Report. The MBC has expressed concerns that the data presented in the report may not be sufficient to make a decision as to appropriate prescribing practices for physicians working with foster youth.
The Board has, in the meantime, developed a notification process whereby individuals in the healthcare delivery system for foster youths can directly contact MBC staff if they believe a physician is inappropriately prescribing medication to children in foster care. After a complaint or notification is made, MBC staff will directly contact DSS to obtain all de-identified patient information for the foster child and the prescriber. The Board can then determine whether or not it will need patient records. DSS and the MBC can then obtain these patient records through a court order so that the Board can proceed with an investigation into the prescribing physician.
- Data Sharing Efforts. MBC currently has a data user agreement (DUA) with DHCS and DSS in order to allow the MBC to receive information that does not breach the confidentiality of a patient. The agreement is based on conversations dating back to 2014 regarding the data needed for the MBC to identify physicians who may be inappropriately prescribing psychotropic medications to foster children. Upon receipt of its first set of data under the DUA, MBC enlisted a pediatric psychiatrist review the data. The physician determined that the information provided through the agreement was not substantive enough to allow MBC to identify instances of any inappropriate prescribing and noted that additional information to assist in this effort would include the diagnosis associated with medication prescribed, the dosage of medication prescribed, the schedule or timing of dosage of medication prescribed and the weight of child or adolescent.
- Prior Related Legislation. SB 238 (Mitchell, Chapter 534, Statutes of 2015) required certification and training programs for foster parents, child welfare social workers, group home administrators, public health nurses, dependency court judges and court appointed council to include training on psychotropic medication, trauma, and behavioral health, as specified, for children receiving child welfare services. The bill also required Judicial Council to amend and adopt rules of court and develop appropriate forms pertaining to the authorization of psychotropic medication for foster youth, on or before July 1, 2016.
SB 253 (Monning) of 2015 was also intended to respond to troubling reports about overprescribing of psychotropic medication to foster youth and would have provided a detailed framework the court must use when determining whether to approve the administration of psychotropic medication to wards and foster children, and required judicial oversight of any ongoing treatment to help ensure that these powerful drugs are only used when medically necessary and appropriate for the particular child and that such usage is very carefully monitored to ensure any benefits of the medication are not outweighed by its short- and long-term risks. The bill also would have required an order of the juvenile court authorizing psychotropic medication to require clear and convincing evidence of specified conditions and would have prohibited the authorization of psychotropic medications without a second independent medical opinion under specified circumstances, as well as would have prohibited the authorization of psychotropic medications unless the court was provided documentation that appropriate lab screenings, measurements, or tests have been completed, as specified. (Status: The bill was placed on inactive in the Assembly.)
SB 484 (Beall, Chapter 540, Statutes of 2015) required DSS to establish a methodology for identifying group homes that have levels of psychotropic dug utilization warranting additional review, and to inspect identified facilities at least once a year, as specified. The bill permitted DSS to share information and observations with the facility and to require the facility to submit a plan within
30 days to address identified risks, as specified.
SB 319 (Beall, Chapter 535, Statutes of 2015) expanded the duties of the foster care public health nurse to include monitoring and oversight of the administration of psychotropic medication to foster children, as specified.
- Arguments in Support. Numerous groups such as the Youth Law Center, Consumer Attorneys of California, and First Focus Campaign for Children support SB 1174, citing the frequency of psychotropic drug prescription among foster youth. These groups call for an appropriate oversight mechanism that can help identify outlying prescribers. They argue that SB 1174 will enable MBC to confidentially collect and analyze data, and, when warranted, conduct investigations of physicians who frequently prescribe over the recognized safety parameters for children.
- Arguments in Opposition. The California Medical Association (CMA) is concerned that SB 1174 adds another bureaucratic layer to a process that is already highly regulated and are concerned that the bill will delay or prevent some youth from receiving appropriate treatments as well as discouraging physicians from working within the Medi-Cal program. CMA notes that because the medical records are protected, the data that provided to the MBC will provide an incomplete picture without the underlying medical records which can only be obtained through a court order or if the patient waives confidentiality. CMA believes that investigations will target physicians working specifically within the Medi-Cal system or mental health professionals who specialize with patients with severe mental health difficulties. CMA cites the example of a psychiatrist who works exclusively in Juvenile Hall or group homes as potentially having a much higher rate of psychotropic prescriptions to children than a psychiatrist providing services to the general population which will trigger that physician being investigated.
CMA believes that this bill has the potential to discourage physicians from working within the Medi-Cal program which is already suffering from access problems as well as cause some physicians not to prescribe psychotropic medications even if they feel it is an appropriate treatment option.
CMA is requesting an amendment to ensure that educational outreach be required before MBC could initiate an investigation based on the data received from DHCS. They suggest that the guidelines could be a useful tool as the centerpiece of educational outreach.
SUPPORT AND OPPOSITION:
Support
Bay Area Youth Center
California Youth Connection
Consumer Attorneys of California
Consumer Watchdog
Family Voices of California
First Focus Campaign for Children
John Burton Foundation
Kids in Common, a program of Planned Parenthood Mar Monte
Madera County Department of Social Services
Peers Envisioning and Engaging in Recovery Services
Therapists for Peace and Justice
Woodland Community College Foster and Kinship Care Education
Youth Law Center
One individual
Oppose
California Medical Association
-- END --
Discussed in Hearing
Senate Floor
Assembly Floor
Assembly Standing Committee on Appropriations
Assembly Standing Committee on Business and Professions
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Business, Professions and Economic Development
Bill Author
Bill Co-Author(s):